Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Analysis of the intricate effects of polyunsaturated fatty acids and polyphenols on inflammatory pathways in health and disease

Denisa Margină, Anca Ungurianu, Carmen Purdel, George Mihai Nițulescu, Dimitris Tsoukalas, Evangelia Sarandi, Maria Thanasoula, Tatiana I. Burykina, Fotis Tekos, Aleksandra Buha, Dragana Nikitovic, Demetrios Kouretas, Aristidis Michael Tsatsakis

**Corresponding author.** University of Crete, Faculty of Medicine, Department Forensic Sciences Laboratory of Histology-Embryology, Medical School, University of Crete, 71003, Heraklion, Greece.

**E-mail addresses:** anca.ungurianu@umfcd.ro (A. Ungurianu), tsatsaka@uoc.gr (A.M. Tsatsakis).

Abstract

Prevention and treatment of non-communicable diseases (NCDs), including cardiovascular disease, diabetes, obesity, cancer, Alzheimer’s and Parkinson’s disease, arthritis, non-alcoholic fatty liver disease and various infectious diseases; lately most notably COVID-19 have been in the front line of research worldwide. Although targeting different organs, these pathologies have common biochemical impairments – redox disparity and, prominently, dysregulation of the inflammatory pathways. Research data have shown that diet components like polyphenols, poly-unsaturated fatty acids (PUFAs), fibres as well as lifestyle (fasting, physical exercise) are important factors influencing signalling pathways with a significant potential to improve metabolic homeostasis and immune cells’ functions. In the present manuscript we have reviewed scientific data from recent publications regarding the beneficial cellular and molecular effects induced by dietary plant products, mainly polyphenolic compounds and PUFAs, and summarize the clinical outcomes expected from these types of interventions, in a search for effective long-term approaches to improve the immune system response.

1. Introduction

Non-communicable diseases (NCDs), the silent epidemic, are responsible for the majority of deaths in developed countries and their prevalence at a younger age was observed increasingly in the last years (WHO, 2013, 2018). Cardiovascular disease (CVD), diabetes, obesity, cancer, Alzheimer’s and Parkinson’s disease, arthritis, non-alcoholic fatty liver disease (NAFLD) and chronic obstructive disease are some of the most common NCDs sharing common features. Research shows that redox impairments and chronic low-grade inflammation generate a vicious biochemical self-propagating cycle, constituting the molecular pathological root of these diseases. In the context of modern lifestyle, stress factors including malnutrition/overnutrition, smoking or sedentary routine are initiating factors for the impairment of inflammatory pathways contributing to the development of NCDs. Furthermore, in real-life scenarios, people experience uncontrolled simultaneous exposure to many environmental chemicals, hence novel methodological approaches simulating real-life exposures are being developed under the name real life risk simulation (RLRS) with the aim to assess the potential adverse health effects of long-term exposure to chemical mixtures.
(Hernandez et al., 2019; Hernandez and Tsatsakis, 2017; Tsatsakis et al., 2016, 2019a). According to WHO, 80% of NCDs-related deaths could be prevented by changes in these modifiable risk factors, and recent evidence identified unhealthy diet as the biggest risk factor for NCDs-related deaths (Collaborators, 2019; WHO, 2018).

Under physiological conditions, inflammation is a response to harmful stimuli (pathogens or tissue lesions), a cellular adaptive mechanism aiming to restore tissue homeostasis (Medzhitov, 2008). Inflammatory responses are self-limited through specific checkpoints that curb the progression and promote the resolution of inflammation (Basil and Levy, 2016; Serhan and Savill, 2005). Failure due to the deleterious alterations of the inflammatory pathways brings about the excessive release of pro-inflammatory molecules, leading to chronic low-grade inflammation and fibrosis (Norling and Serhan, 2010; Russell and Schwarz, 2014). The persistence of this usually short-term defence mechanism leads to a chronic inflammatory state, transitioning from solution to cause, becoming in fact a lesion-inducing factor for the affected tissues. This may be a result of the dysregulation of several cellular pathways involving cyclooxygenase-2 (COX-2), signal transducer and activator of transcription 3 (STAT3), matrix metalloproteinase-9 (MMP-9), nuclear factor kappa B (NF-kB), cytokines with inflammatory outcome: interleukins (IL-1, IL-6, IL-8), tumour necrosis factor alpha (TNF-α), cell adhesion molecules and chemokines, etc. Of note, the resolution of the inflammatory process cannot be simply switched off by restricting the synthesis of the pro-inflammatory molecules, requiring cellular intervention through anti-inflammatory and pro-resolving molecules (Minihane et al., 2015; Ortega-Gomez et al., 2013; Serhan et al., 2008).

Mitigating the pathological pathways associated with chronic low-grade inflammation through pharmacological agents but, more importantly, through diet and lifestyle changes might constitute an effective strategy in the prevention of NCD and NCD-related deaths. In the current review, we overview recent facts from molecular and animal studies to human clinical reports regarding the intricate pathways that are affected by some of our dietary habits, also discussing the next steps that ought to be taken in addressing these parameters.

2. Cellular and molecular inflammatory-related mechanisms

In physiological conditions, NF-κB (a heterotrimer with p65 and p50 subunits associated with the IκBα inhibitory subunit) is localized to the cytoplasm. Under the effect of inflammatory stimuli (for instance cytokines – IL-8, IL-1β, IL-6, or TNF-α, UV exposure, etc.), the heterodimer dissociates, IκBα is degraded, and the two components, p50 and p65, translocate into the nucleus binding the promoter regions from different genes that are involved in initiating several cellular pathways linked to chronic diseases, tumorigenesis, angiogenesis and metastasis. Among the genes regulated by NF-κB are the ones for the expression of TNF-α, COX-2, MMP-9, nitric oxide synthase – the inducible form (iNOS), cytokines (IL-1, IL-6 and IL-8), 5-lipoxygenase (5-LOX), vascular endothelial growth factor (VEGF); all of these genes, when up-regulated fire-up the vicious circle constituted from oxidative stress and inflammation (Aggarwal, 2009; Kawabata et al., 2012; Kunnumakkara et al., 2018; Nimigean et al., 2018, 2019; Poll et al., 2018a, 2018b; Reuter et al., 2010). Interestingly, the NF-κB cascade is also activated by some factors that affect the circadian rhythm, such as aging or sleep deprivation. In animal models, high-fat diets as well as obesity – pro-inflammatory states, are directly correlated with a decrease of the amplitude of circadian activity and rhythmic gene expression, thus, suggesting that the inflammatory pathways are directly responsible for influencing the circadian clock (Gachon et al., 2018; Kohsaka et al., 2007; Osorio et al., 2016).

Another important inflammatory pathway involves STAT3, a cytokine protein that is phosphorylated by JAK 1, 2, and 3 (Janus-activated kinases), under the influence of inflammatory stimuli. STAT3 reaches the nucleus and functions as a transcriptional factor, stimulating the synthesis of inflammatory mediators (Pandurangan et al., 2015; Sung et al., 2012). The MAPK/ERK (mitogen-activated protein kinases) group, including stress activated protein-kinases p38, JNK (c-Jun N-terminal kinases) and ERK (extracellular signal-regulated kinases), is also involved in the inflammatory cascade as a response to a detrimental stimulus (Liang et al., 2016). Also, to the family of transcription factors we can comprise nuclear factor erythroid 2-related factor 2 (Nrf2), activator protein-1 (AP-1), nuclear factor of activated T cells (NFAT) or hypoxia-inducible factor-1α (HIF-1α), all being recognized for their role in stress response as well as in mediating inflammation (Panieri et al., 2020; Reuter et al., 2010) (Fig. 1).

Pro-inflammatory stimuli activate several regulatory cell processes. The activation of IKK (IκBα kinase) causes the cleavage of NF-κB, associated with nuclear translocation for p50 and p65, while that of MAPK directs the phosphorylation of p38, ERK and JNK. Also notable are the dimerization of STAT3 and the association of HIFα with HIFβ, all resulting in the activation of several transcription factors or direct stimulation of gene expression, targeting pro-inflammatory molecules. However, an increased expression of antioxidant enzymes can be encountered due to decreased degradation of Nrf2 and its activation of ARE, post-nuclear translocation and association with Maf. The activation of all the inflammation-related pathways, along the cellular and metabolic disturbances that follow, contributes to the high occurrence of obesity and associated pathology (diabetes mellitus, metabolic syndrome, CVD, Alzheimer’s disease, etc.), especially under the influence of modern life factors (malnutrition, smoking, pollution, low physical activity) (De Lorenzo et al., 2016; Georgescu et al., 2014; Georgescu, 2014; Gustafson et al., 2007; Libby, 2012; Ungurianu et al., 2017, 2019a; Wang et al., 2004; Zanfirescu et al., 2019). The obese state is characterized by low-grade systemic inflammation, with impaired synthesis of adipokines and activation of pro-inflammatory signalling pathways leading to insulin resistance. Adipose tissue inflammation is one of the determining factors of obesity complications, impairing the adipocyte secretory function and hormonal balance.

Physiologically, adipose tissue resident macrophages, displaying both a pro-inflammatory and anti-inflammatory phenotype, are involved in several housekeeping processes (differentiation of pre-adipocytes, abraction of necrotic and apoptotic cells, angiogenesis adjustment, etc.). The expansion of adipose tissue, due to long-lasting overnutrition, induces prolonged hypoxia (the activation of HIF-1α), and consequent inflammation as monocytes infiltrate in the hypoxic region and become pro-inflammatory macrophages, process during which TNF-α, monocyte chemotactic protein (MCP-1), IL-6, MMPs, IL-8, VEGF are released. Further, the inflammatory response elicited by dysfunctional adipocytes, hypoxia, adipocyte expansion, and impaired fatty acids storage is accelerated by formation of reactive species, either oxygen (ROS) or nitrogen (RNS) (Crewe et al., 2017; Demaria et al., 2014; Fujisaka et al., 2013; Margina et al., 2012; Pasarica et al., 2009; Paun et al., 2015; Schipper et al., 2012; Traylor, 2014).

Metabolic impairments associated with obesity may contribute to the release of inflammatory mediators (IL-18, IL-1β) due to the stimulation of the NLR (nucleotide-binding oligomerization domain (NOD)-like receptors) family pyrin domain-containing 3 (NLRP3) which forms a cytoplasmic complex known as the NLRP3 inflammasome, with direct modulating role on the innate immune system. This pathway is involved in obesity as well as associated inflammation, and among the endogenous danger signals activating it we can find glucose and ROS. Also, literature data states that IL-1β, IL-18 are produced as an effect of TLR (Toll-like receptors)-mediated NF-κB activation, thus pointing out to the interaction of different signalling pathways (Fettelschoss et al., 2011; Tschopp and Schroder, 2010; Zhou et al., 2010).

In the light of these pathways, consolidated research is needed to point out in ability of some dietary components, based on the RLRS approach, to reduce the expression of inflammatory molecules and resolve the ROS-inflammation cycle, in order to diminish the risk for long-time comorbidities associated with obesity/metabolic
impaired.

3. Microenvironment originating inflammatory cues

The extracellular matrices (ECMs), are complex, multi-constituent meshes that surround and support cells in tissues, with a regulatory role in all biological processes, as well as in tissue organization (Hynes, 2009). The ECMs are composed of fibrillar proteins and proteoglycans, as well as glycosaminoglycans specifically organized as modules or domains. The ECM suprastructure can be envisaged as a "platform" receiving, and simultaneously, delivering a myriad of signals to cells that are crucial to homeostasis, but also contributing to the progression of various pathologies (Sifaki et al., 2006; Tzanakakis et al., 2018, 2019). Importantly, the inflammatory-mediated alterations in the ECM result in release of active mediators crucial to disease progression (Kavasi et al., 2017; Neagu et al., 2019; Nikitovic et al., 2015). Noteworthy, the effects exerted by remodelled ECM are cell and tissue type dependent exerting thus, specific influence to discrete tissue compartments (Nikitovic et al., 2014a).

Recent developments highlighted the importance of ECM remodelling in metabolic disease and obesity as well as the associated inflammation (Ruiz-Ojeda et al., 2019). Indeed, it was suggested that both the specific remodelling of adipose tissue ECM organization and dysregulated intracellular signalling processes may be correlated with obesity-associated insulin resistance (Guzman-Ruiz et al., 2020). The main components of adipose tissue ECM are collagens, fibronectin and laminin (Mori et al., 2014). Minor constituents include osteopontin, hyaluronan (HA), thrombospondins, MMPs, as well as A disintegrin and metalloproteinase domain-containing protein (ADAMs), and contribute significantly to ECM remodelling and the regulation of adipose tissue functions (Lin et al., 2016).

The main characteristic of obesity is an increase in lipid tissue infiltration due to the hypertrophy of existing adipocytes, as well as due to the hyperplasia of adipocytes resulting from de novo adipogenesis from precursor stem cells (Schoetil et al., 2018). Indeed, it was postulated that the ECM, in a spatial as well as temporal manner, regulates adipogenesis (Soukas et al., 2001). In addition to adipocyte deposition, a notable migration of macrophages and vascular cells was correlated to changes in the ECM structure. This remodelling leads to the release of active mediators that can affect immune cells’ recruitment and activation, facilitating the inflammatory state of lipid tissue. Furthermore, the strong upregulation of obese adipose tissue ECM components, including collagen and osteopontin, was suggested to initiate the necrosis of adipocytes, hence the proliferation of immune cells, leading to tissue inflammation and metabolic dysfunction (Catalan et al., 2012; Ruiz-Ojeda et al., 2019). Thus, the overexpression of endotrophin, resulted from the cleavage of the α-3 chain of collagen VI (Col6α3), facilitates the deposition of fibrotic collagen and initiates adipose tissue inflammation and insulin resistance (Sun et al., 2014). A recent study demonstrated that the expression of MMP14 is strongly upregulated in the adipose tissue of transgenic obese mice. Interestingly, MMP14 proteolytic activity results in the release of endotrophin with concurrent formation of enlarged adipocytes and increase in body weight, altered lipid metabolism and insulin resistance (Li et al., 2020). Furthermore, Springer et al. recently demonstrated a link between alterations in the ECM of obese women and breast cancer. Thus, enhanced adipose tissue interstitial fibrosis facilitates the generation of M2/M1 type macrophages pattern similar to that of tumour-associated macrophages, as well as the generation of associated inflammatory cues (Springer et al., 2019).

Under these conditions a paracrine loop consisting of free fatty acids and TNF-α is established among adipocytes and infiltrating macrophages that enhances inflammation-mediated alterations in the adipose tissue (Engin, 2017). Recently, lumican, a small leucine-rich proteoglycan (Nikitovic et al., 2014b), was shown to be overexpressed in ECM of subcutaneous fat of insulin resistant obese individuals. Lumican was demonstrated to alter the organization of collagen I, dysregulate adipogenesis and trigger oxidative stress, facilitating the pathology of obesity-associated insulin resistance (Guzman-Ruiz et al., 2020). A
separate study showed that the effect of lumican was diet-dependent and correlated to adipose tissue inflammation. Indeed, the same authors suggest that the ECM protein lumican could pose a convergent point among the ECM, the glucose homeostasis and the metabolic syndrome (Wolf et al., 2019).

Osteopontin, an ECM glycoprotein, excessively secreted by adipose tissue macrophages (Nomiyama et al., 2007) enhances adipose tissue inflammation and facilitates the onset of insulin resistance (Aouadi et al., 2013). Another important ECM component, the glycosaminoglycan HA, has been strongly correlated to increased inflammatory burden, including cancer-associated (Nikitovic et al., 2015) and sterile inflammation (Kavasi et al., 2017, 2019; Nikitovic et al., 2014a). Indeed, the generated LMWHA fragments can trigger a Toll-like receptor 4 (TLR4)/NF-κB signalling pathway to regulate inflammatory genes transcription in immune cells (Kavasi et al., 2017; Termeer et al., 2002). Interestingly, HA levels were increased in various tissues of type-2 diabetes mellitus (T2DM), but not in type-1 (T1DM) subjects, and independent of glycemic control. Taking into account that T2DM, in contrast to T1DM, is linked with systemic inflammation, it was suggested that inflammatory factors and not hyperglycaemia upregulate HA levels (Nagy et al., 2019). Importantly, it was demonstrated that the expression of genes involved in the metabolism of HA was positively correlated to the process of adipocyte differentiation (Allingham et al., 2006). Recently, it was shown that HA exerts inhibitory effects in vitro regarding adipogenesis of 3T3-L1 cells, whereas downregulating HA prevented insulin resistance and NAFLD differentiation (Allingham et al., 2006). Recently, treatment of HFD-fed obese mice with a stable hyaluronidase complex, where human C57BL/6J mouse model (Ji et al., 2014). Moreover, treatment of HFD-fed obese mice with a stable hyaluronidase complex, where human recombinant hyaluronidase was Pegylated, was shown to decreases adiposity, adipose tissue inflammation and insulin resistance (Kang et al., 2013).

A hallmark of metabolic diseases is a high NADH/NAD+ ratio, originating from excessive electron supply. This dysregulation results in an altered mitochondrial function and sirtuin-3 (SIRT-3) activity, which result in oxidative stress and distorted fatty acid β-oxidation (Cortes-Rojo et al., 2020). Increased ROS production was shown to induce excessive remodelling of the ECM in a pathologic milieu (Nikitovic et al., 2013). Thus, oxidative stress induced by high-glucose levels, in rat glomerular mesangial cells, resulted in an increased deposition of collagen IV and fibronectin, through the involvement of the TXNIP-NLRP3 inflammasome signalling (Wang et al., 2017). Importantly, the remodelling of renal ECM is involved in the progression of diabetic nephropathy, one of the most serious complications of diabetes mellitus. Treatment aimed at downregulating ROS generation, such as the utilization of dihydroquercetin (DHQ), an important natural dihydroflavone, attenuated the activation of NLRP3 inflammasome and the subsequent of increased deposition to ECM of renal fibrosis-associated proteins upon exposure of renal cells to high glucose levels (Ding et al., 2018).

These data highlight the complex interactions between the ECM, inflammation, and metabolic diseases. The reorganization of the ECM as well as ECM-originating pro-inflammatory cues needs to be taken account when designing efficient therapy for inflammation associated disease. Dietary measures might constitute important means to mitigating these pathological pathways.

4. Carbohydrate-restricted diets and their effects on inflammation

Postprandial hyperglycaemic spikes are linked to ROS generation and inflammation, as ROS, via the NF-κB pathway, promote the expression of pro-inflammatory molecules such as MCP-1, TNF-α, IL-6, IL-1β, along AP-1, as well as FOXO. These molecules interfere with the insulin signalling pathway, add to the insulin resistance progress (Lumeng et al., 2008; Weisberg et al., 2003) and affect blood levels of some inflammatory biomarkers more than chronic hyperglycaemia (Barrea et al., 2018; Della Corte et al., 2018). Healthy diets, based on low glycemic index food, resulting in a lesser increase of glycemia and lipemia in postprandial settings, induced a lower production of pro-inflammatory molecules (Barrea et al., 2018; Della Corte et al., 2018). In preclinical studies, a strict restriction of carbohydrate intake was shown to promote inflammation and shorten lifespan in senescence-prone mice, increasing IL-6 and IL-1β, compared to diets rich in fats (He et al., 2019), with no alteration of serum glucose or insulin versus a standard diet (Nilsson et al., 2016).

However, a long-term carbohydrate-restricted, high-fat diet promoted a pro-inflammatory state (He et al., 2018), impairing glucose (Ellenbrook et al., 2014; He et al., 2018) and lipid metabolism (Garbow et al., 2011), affecting liver (Garbow et al., 2011) and pancreatic function (Ellenbrook et al., 2014; He et al., 2018). A high intake of saturated fats also led to an increase in pro-inflammatory molecules’ levels (IL-1β or leptin) (Andre et al., 2017), although a short-term diet enrichment with ketone diesters induced anti-inflammatory effects in NLRP3-mediated inflammatory maladies (Youm et al., 2015). Post-prandial cord injury, a ketogenic diet reduced oxidative stress as well as inflammation, suppressing the NF-κB pathway (Andre et al., 2017; Lu et al., 2018), while activating Nrf2, resulting in lowering TNF-α, IL-1β, IFN-γ expression (Lu et al., 2018). The highlights of these studies are presented in Tables 1 and 2.

On the other hand, long-term diets abundant in highly processed and high glycemic index products seem also to induce a pro-inflammatory metabolic profile (Gomes et al., 2020; Luz et al., 2018). These recent reports suggest that not only the quantity, but also the type of carbohydrates and fats consumed is the major influencing factor of systemic inflammatory status. Thus, clinically, even a 4-day low-carbohydrate diet intervention improved the insulin and fasting plasma glucose levels in T2DM patients (Myette-Cote et al., 2018). When comparing low-carb to low-fat diets in diabetics, some older studies reported a similar effects on cardiovascular risk markers (Davis et al., 2011), while more recent ones asserted the beneficial effects of restricting carbohydrates on the systemic low-grade inflammation, reducing IL-6 (Asle Mohammadi Zadeh et al., 2018; Jonasson et al., 2014), resistin, leptin (Asle Mohammadi Zadeh et al., 2018), E-selectin, sICAM (Davis et al., 2011) and increasing adiponectin (Asle Mohammadi Zadeh et al., 2018). Furthermore, the improvement of systemic inflammatory status was also reported in obese adults, with no T2DM or CVD (Hu et al., 2015).

Switching to a very strict low-carb diet was associated with an increase of systemic inflammation in apparently healthy subjects (Rosebaum et al., 2019), while in subjects with metabolic syndrome or obesity, a short-term ketogenic diet yielded beneficial cardiometabolic effects (Gyorkos et al., 2019; Ruth et al., 2013). In T2DM patients, a one-year nutritional ketosis intervention resulted in a lower cardiovascular risk (Bhanupriya et al., 2018). Importantly, these beneficial effects are modulated by physical activity (Alves et al., 2016; Asle Mohammadi Zadeh et al., 2018; Myette-Cote et al., 2018), and by the diet supplement with nuts (Hou et al., 2018), soy (Kani et al., 2017), or even carefully choosing the types of ingested carbohydrates. In obese and overweight adolescents and adults, a diet based on low glycemic index food improved inflammation, metabolic as well as cardiovascular risk factors (Rouhani et al., 2016), while the addition of functional foods resulted in further benefits (Izadi et al., 2018). Also, the consumption of complex carbohydrates led to a decline of pro-inflammatory molecules’
level in pregnant women (Hernandez et al., 2016). The results of most recent clinical studies concerning the link between low-carb diet and systemic inflammation are summarized in Table 3.

So, adding high-fiber and exercise to a low-index carbohydrate diet has beneficial effects on inflammatory profile of T2DM and obese patients while low-carb and low-fat diets induce the same type of effects on cardiovascular risk markers of diabetes patients.

5. Mediterranean diet and the impact on inflammation

The Mediterranean diet (MD) is based on the dietary pattern found in the Mediterranean basin (Greece, southern regions of Italy and Spain), and includes high amounts of fresh vegetables and fruits, seeds, nuts, along with olive oil and whole grain cereals. Milk, cheese, yogurt, eggs, fish and poultry are consumed in moderate amounts, as is wine (especially red), with low amounts of red meat and sugary deserts (Martinez-Gonzalez et al., 2014; Tosti et al., 2018). This diet is abundant in

| Table 1: Clinical studies regarding the effect of high fibre intake on inflammatory markers in obesity and associated pathology. |
| Design | Population | Dietary intervention | Outcome | Reference |
| Randomized cross-over trial | 50 Danish subjects with high risk of metabolic syndrome | two 8-week periods of whole grain intake (179 ± 50 g/day)/refined grain (maximum 13 ± 10 g/day of whole grain), divided by a washout period of ≥6 weeks. | ↓ body weight, serum inflammatory markers (IL-6, CRP) | Roager et al. (2019) |
| Double-blind, crossover, placebo-controlled, randomized study | 45 metabolic syndrome patients risk factors | galactooligosaccharide mixture intervention to increase dietary fibre content, with a 4-wk wash-out period between interventions | ↓ faecal calprotectin, CRP | Vulevic et al. (2013) |
| Randomized controlled trial | 143 individuals with metabolic syndrome | 12 weeks of rye and whole wheat was compared with a diet containing the equivalent amount of refined cereal foods | no significant effects on the expression of inflammatory markers’ genes or insulin sensitivity | Giacco et al. (2013) |
| Randomized crossover study | 19 adults with metabolic syndrome | 4-week of arabinoxylan and resistant starch enriched diet versus Western-style, low-fibre diet | ↓ faecal calprotectin, IL-23A and Nf-κB | Hald et al. (2016) |
| Crossover intervention study | 25 hypercholesterolemic subjects | 5-week intervention using low fibre and high fibre diet, separated by a 3-week washout. | ↓ CRP and fibrinogen | Johansson-Person et al. (2014) |
| Randomized controlled trial | 68 overweight with prediabetes | 12 weeks of 45 g/d of high-amylose maize (RS2) versus an isooscalic amount of amylopectin (control) | ↓ TNF-α, no change in insulin sensitivity | Peterson et al. (2018) |
| Randomized controlled trial | 166 subjects with features of metabolic syndrome | 4-week using healthy diet (fruits and vegetables, berries, whole-grain products, rapeseed oil, three fish meals per week) compared to a regular Nordic diet | Control diet: ↑ IL-1Ra (versus healthy diet group) | Uusitupa et al. (2013) |
| Crossover study | 10 healthy subjects | Subjects received either 910 calorie high-carbohydrate/high-fat meal or a standard meal according to American Heart Association (based on fruit and fibre) during the first visit and the other meal during the second visit | ↓ oxidative stress (bloodlevels of TBARS, LPS, FFA) and proinflammatory markers (TNFs, IL-1β) | Randona et al. (2015) |
| Randomized controlled trial | 28 T2DM patients | Subjects received either Healthy Diet (n - 44), a whole-grain-enriched diet (n - 42) or a control (n - 45) diet, separated by a 3-week washout. | ↓ CRP in brown rice group | Kondo et al. (2017) |
| Parallel design, dietary intervention trial | 104 subjects with metabolic syndrome risk | Subjects received Healthy Diet (n - 44), a whole-grain-enriched diet (n - 42) or a control (n - 45) diet, separated by a 3-week washout. | | de Mello et al. (2011) |
| Cross-over, randomized, placebo-controlled, double-blind, study | 12 overweight and obese subjects | Subjects received 20 g/day of inulin (high-fermentable fibre) and cellulose (low-fermentable fibre) for 42 days | IPE: ↓ IL-8 levels (versus cellulose) | Chambers et al. (2019) |
| Crossover clinical study | 18 subjects at low-to-moderate cardiometabolic risk | Subjects received breakfast either rich in fibre, unsaturated fatty acids (unSFA) or saturated fatty acids (SFA) for 4 weeks | | |
| Interventional diet study | 21 overweight/obese children | Subjects were placed on a regimen of low-fat, high-fibre diet and daily exercise for 2 weeks | ↓ PAI-1, TNF-α, IL-6, IL-8, resistin, insulin, amylin, leptin, and IL-1ra | Izdawun et al. (2012) |
| Randomized, placebo-controlled study | 31 hemodialysis patients | Patients received either resistant starch or placebo supplementation, for 4 weeks | ↓ IL-6 and TBARS | Espalhado et al. (2018) |
| Randomized controlled clinical trial | 55 women with T2DM | Subjects received 10 g resistant dextrin/day for 8 weeks | ↓ IL-6, TNF-α and MDA | Alamsharzadeh et al. (2015) |
| Randomized cross-over double-blind placebo-controlled trial | 17 obese knee osteoarthritis patients | Patients received freeze-dried strawberries or placebo for 2 periods of 12 weeks with 2 weeks wash-out | ↓ TNF-α and 4-HNE | Basu et al. (2018) |
| Randomized study | 59 T2DM patients | Patients received metformin, acarbose and either a high fibre or a low fibre diet intervention for 8 weeks | Low fibre group: ↓ IL-18 | Nowotny et al. (2015) |
| Crossover study | 33 healthy, middle-aged adults | Patients received either high or low in wholegrain intervention for 6-week periods, separated by a 4-week washout. | Whole grain: a slight decrease of IL-10 and CRP | Ampatzoglou et al. (2016) |
| Observational study | 8 subjects with impaired fasting glucose | Subjects received (1) high-fibre formula; (2) high-monoamnattured fatty acid formula or (3) control formula | ↓ HbA1c | Kim et al. (2013) |
| Randomized controlled clinical trial | 60 females with T2DM | Patients received 10 g/d of resistant starch or placebo for 8 weeks, respectively | ↓TNF-α, no effect on IL-6 or CRP | Gargari et al. (2015) |
| Crossover clinical trial | 80 overweight subjects | Subjects received 10 g resistant dextrin/day for 8 weeks. Fibre group: ↓ IF-γ and TNF-α | Fibre group: ↓ | Monfort-Pires et al. (2018) |
| Observational study | 49 T2DM females | Patients received either 10 g/day inulin or maltodextrin/diet for 8 weeks | Inulin: ↓ CRP, TNF-α and LPS | Dehghan et al. (2014a) |
| Randomized controlled clinical trial | 52 overweight/obese women with T2DM | Patients received either 10 g/d of oligofructose-enriched inulin or maltodextrin (control) for 8 weeks | ↓ CRP, TNF-α and LPS | Dehghan et al. (2014b) |
| Randomized crossover clinical trial | 44 overweight/obese girls | Subjects received either whole-grain or control for 2 periods of 6 weeks with 4-week washout period | Whole grain: ↓ CRP, ICAM-1 and leptin | Hajishahemi et al. (2014) |
that MD exerts a hormetic effect, similar to caloric restriction, high most likely their combined synergistic effects contribute to reducing the CRP, E-selectin, P-selectin, TNF-α, IL-1β, IL-6) and of mRNAs of pro-inflammatory genes related to inflammation, metabolism and signal transduction processes equilibrium (Martucci et al., 2017). Epigenetic regulation was lighting the Nrf2 pathway, regulating the pro-/anti-inflammatory pro

In recent years, the effects of a diet similar to MD started to be investigated: the Nordic diet (ND). Similarly, ND is based on fruits, especially berries, and vegetables, fish, whole grains, and includes low virgin olive oil (Lankinen et al., 2019; Magnusdottir et al., 2017). Literature reports olive oil is specific for the Mediterranean basin, the ND includes canola especially berries, and vegetables, fish, whole grains, and includes low minerals and vitamins, antioxidants and phytochemicals (Tosti et al., 2018). Although several of its components exerted beneficial actions, most likely their combined synergistic effects contribute to reducing the systemic inflammatory burden (Tosti et al., 2018). Some authors posit that MD exerts a hormetic effect, similar to caloric restriction, highlighting the Nrf2 pathway, regulating the pro-/anti-inflammatory processes equilibrium (Martucci et al., 2017). Epigenetic regulation was also hypothesized, especially due to components found in nuts and extra virgin olive oil, which were reported to alter the methylation of some genes related to inflammation, metabolism and signal transduction (Arpon et al., 2016, 2017).

In healthy subjects, even one MD-style meal was shown to reduce the expression of pro-inflammatory molecules (De Lorenzo et al., 2017), with no differences between sexes regarding effects on systemic inflammatory status (Bedard et al., 2015). In elderly individuals, a MD intervention lead to lower glycoxidative impairment (Lopez-Moreno et al., 2018) and inflammatory response (Camargo et al., 2012; Yubero-Serrano et al., 2012), paralleled to a diet based on saturated fatty acids (Fig. 2).

A marked reduction of inflammatory molecules (C reactive protein – CRP, E-selectin, P-selectin, TNF-α, IL-1β, IL-6) and of mRNAs of pro-inflammatory genes was reported in overweight and obese individuals which adhered a classic or modified MD (Bekkouche et al., 2014; Marques-Rocha et al., 2016; Paoli et al., 2015; Rallidis et al., 2017; Tripp et al., 2019). Furthermore, in diabetics and patients with high cardiovascular risk, MD determined a significant reduction of serum levels of CRP, interleukins and adhesion molecules (Casas et al., 2014; Ceriello et al., 2014; Maiorino et al., 2016; Mayr et al., 2018). In a group of asthmatic children, MD supplemented with 150g cooked fish twice a week resulted in significantly improved pulmonary function and markedly increased docosahexaenoic acid (DHA) levels and improved omega-6 to omega-3 ratio (Papamichael et al., 2019). The recent clinical trials addressing the relationship between MD and inflammation are summarized in Table 4.

In recent years, the effects of a diet similar to MD started to be investigated: the Nordic diet (ND). Similarly, ND is based on fruits, especially berries, and vegetables, fish, whole grains, and includes low amounts of processed red meat and is almost lacking saturated fats. As olive oil is specific for the Mediterranean basin, the ND includes canola oil (Lankinen et al., 2019; Magnusdottir et al., 2017). Literature reports are reviewed elsewhere (Lankinen et al., 2019) and although scarce, they indicated that ND exerted anti-inflammatory effects, as it was able to reduce the serum levels of CRP (de Mello et al., 2011; Lankinen et al., 2019).

Dietary interventions based on Mediterranean/Nordic style induce positive effects on both inflammation and redox stress, both in healthy patients and in those with metabolic impairments (diabetes mellitus, obesity, metabolic syndrome). The hormetic effects induced at the level of the immune system is pointed out by the positive results induced by MD on people with inflammatory phenomena impacting the respiratory

Table 2

| Diet                          | Species                    | Treatment                                      | Observed effects                                                                 | References |
|-------------------------------|----------------------------|------------------------------------------------|-----------------------------------------------------------------------------------|------------|
| Carbohydrate-restricted diet  | Senescence-accelerated prone mice (SAMP8) | 8-week treatment:  
> Control: standard chow  
> High fat diet group (HFD)  
> Carbohydrate-restricted diet group (CRD) | CRD: ↑ IL-6 and IL-1β, ↓ cecum short-chain fatty acids  
LCHF: no change in glycemia, TG, insulin, or non-esterified fatty acid plasma levels | He et al. (2019)  
Nilsson et al. (2016) |
| Scandinavian low-carbohydrate high-fat (LCHF) diet | Female C57BL/6J mice (n = 7/group) | 4-week treatment:  
> standard chow  
> LCHF diet (75% fat 20% protein, and 5% carbohydrates) | In healthy subjects, even one MD-style meal was shown to reduce the expression of pro-inflammatory cytokines and macrophage accumulation, maintaining whole-body insulin responsiveness | Lankinen et al. (2019)  
Ellenbrook et al. (2014)  
Garbow et al. (2011) |
| Ketogenic diet                | Sprague-Dawley Rats with spinal cord injury (n = 18/group) | 4-week treatment:  
> ketogenic diet (KD)  
> standard diet (SD)  
> control (C) | KD: ↑ IL-1β, TNF-α, IFN-γ expression  
↓ α- and β-cell mass | Lu et al. (2018)  
Ellenbrook et al. (2014) |
| Ketogenic diet                | Male C57BL/6J mice | 22-weeks diet intervention:  
> Control: standard chow  
> Ketogenic diet group | KD: ↑ triglycerides, cholesterol, leptin, MCP-1, IL-6, IL-1β,  
↓ α- and β-cell mass | Andre et al. (2017) |
| Ketogenic versus Western diet | C57BL/6J mice | 12-week treatment:  
> very low-carbohydrate, low-protein, and high-fat ketogenic diet (KD)  
> high-simple-carbohydrate, high-fat Western diet (WD)  
> low-fat, polysaccharide-rich control (C) | KD: euglycaemia and hypoinsulinemia + liver lipid accumulation (different pattern compared to WD)  
KD: systemic glucose intolerance, steatosis, cellular injury, endoplasmic reticulum stress (in liver), and macrophage accumulation, maintaining whole-body insulin responsiveness | Garbow et al. (2011) |
| High-saturated fat diet (HFD) | male C57BL/6J mice | 3-week treatment:  
> standard chow  
> HFD (60% fat 20% protein, and 20% carbohydrates)  
> Very HFD (80% fat 16% protein, and 4% carbohydrates) | HFD: ↑ leptin, IL-1β | Andre et al. (2017) |
| Diet supplemented with ketones | Knockout mice model for Muckle-Wells Syndrome and Familial Cold Autoinflammatory syndrome | 1-week treatment:  
> Control: normal chow with 4.5% fat  
> Study group: normal chow supplemented with 20% 1,3-butanediol ketone diesters | Study group: ↑ IL-1β release and caspase-1 activity | Youm et al. (2015) |
| High fat high sucrose diet (HFD) | C57BL/6 J (wild type; WT) male mice | 8-week treatment:  
> Young + normal diet (YND)  
> Young + high fat (YHFD)  
> Old + normal diet (OND)  
> Old + high fat (OHFD) | HFD led to β-cell failure in aged mice, enhanced expression of pro-inflammatory cytokines and macrophage transformation to a more pro-inflammatory phenotype | He et al. (2018) |
### Table 3
Recent reports regarding the relationship between carbohydrate intake and inflammation.

| Diet type                              | Design                  | Population                        | Intervention                                                                 | Effects                                                                 | Ref.                                      |
|----------------------------------------|-------------------------|-----------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------|
| Low-carbohydrate versus high-fat diet  | Randomized crossover    | 11 T2DM patients                  | 4-day diet intervention:                                                      | Glycemia and circulating proinsulin were significantly lower in groups 2 and 3 versus 1; | Mytte-Cote et al. (2018)                   |
|                                        | study                   |                                   | > Group 1: Low-fat low-glycaemic index diet,                                   |                                                                         |                                           |
|                                        |                         |                                   | > Group 2: Low-carbohydrate high-fat diet                                      |                                                                         |                                           |
|                                        |                         |                                   | > Group 3: Low-carbohydrate high-fat diet + 15 min postmeal walks              |                                                                         |                                           |
| Low-carbohydrate versus low-fat diet   | Randomized controlled   | 33 obese T2DM patients            | 8-week diet intervention:                                                      | After the 24-week period:                                               | Eshle Mohammadni Zadeh et al. (2018)     |
|                                        | feeding study           |                                   | > Normal diet                                                                  | LCD: ↑ IL-6, resistin, leptin, glucose, insulin, cholesterol, TG, 1 HDL |                                           |
|                                        |                         |                                   | > Low-carbohydrate diet (LCD)                                                  | LFD: ↑ TNF-α, LDL, HOMA-IR, ↑ adiponectin                               |                                           |
|                                        |                         |                                   | > Low-fat diet (LFD),                                                          |                                                                         |                                           |
|                                        |                         |                                   | > followed by 12 weeks of high intensity interval training 3 days/week, then a 4-week diet intervention, as presented above. |                                                                         |                                           |
| Low-carbohydrate versus low-fat diet   | Randomised controlled   | 51 T2DM patients                  | 6-month diet intervention:                                                      | LCD: ↑ sICAM, E-selectin                                                | Davis et al. (2011)                       |
|                                        | trial                   |                                   | > Low-carbohydrate diet (LCD)                                                  | LFD: ↑ CRP                                                              |                                           |
|                                        |                         |                                   | > Low-fat diet (LFD)                                                            |                                                                         |                                           |
| Low-carbohydrate versus low-fat diet   | Randomised controlled   | 51 T2DM patients                  | 6-month diet intervention:                                                      | LCD: ↑ IL-1Ra, IL-6                                                    | Johansson-Persson et al. (2014)           |
|                                        | trial                   |                                   | > Low-carbohydrate diet (LCD)                                                  |                                                                         |                                           |
|                                        |                         |                                   | > Low-fat diet (LFD)                                                            |                                                                         |                                           |
| Low-carbohydrate versus low-fat diet   | Clinical trial          | 148 obese adults (no diabetes and CVD) | 12-month diet intervention:                                | LCD: ↑ adiponectin [ICAM]                                               | Hu et al. (2015)                          |
|                                        |                         |                                   | > low-carbohydrate diet – LCD, n = 75 (40 g/day)                               |                                                                         |                                           |
|                                        |                         |                                   | > low-fat diet – LFD, n = 73 (<30% kcal/day from total fat, <7% saturated fat) |                                                                         |                                           |
| Low-carbohydrate + nuts                | Randomised controlled   | 51 T2DM patients                  | 3-month diet intervention:                                                      | Improved glycaemic profile versus baseline, no difference between groups regarding IL-5 serum levels | Hou et al. (2018)                        |
|                                        | trial                   |                                   | > Low-carbohydrate diet + peanuts: 60 g for men, 50 g for women (LCD-P)        |                                                                         |                                           |
|                                        |                         |                                   | > LCD + almonds: 55 g for men, 45 g for women (LCD-A)                           |                                                                         |                                           |
| Low-Calorie, Low-Glycaemic Index Diet   | Parallel randomized     | 45 patients with NAFLD            | 8-week diet intervention:                                                      | LGS: ↑ glycaemic indices, CRP                                           | Kani et al. (2017)                       |
|                                        | clinical trial          |                                   | > Group 1: Low-calorie (LC) diet,                                              |                                                                         |                                           |
|                                        |                         |                                   | > Group 2: LC, low-carbohydrate diet                                          |                                                                         |                                           |
|                                        |                         |                                   | > Group 3: LC, low-carbohydrate diet + soy (LCS)                               |                                                                         |                                           |
| Switching to an isocaloric ketogenic   | Clinical study          | 17 men (BMI: 25–35 kg/m²)         | Transitioning from a normal diet (4 weeks–35% fat, 15% protein, 50% carbohydrate) to 4 weeks of an isocaloric KD (80% fat, 5% carbohydrate, 15% protein) | KD: ↑ glyceral, free fatty acids, glucagon, adiponectin, gastric inhibitory peptide, TC, LDL, CRP,2 Fasting insulin, C-peptide, triglycerides and fibroblast growth factor 21 | Rosenbaum et al. (2019)                  |
| diet (KD)                              |                         |                                   | > Low-carbohydrate diet + Prednisone: 60 g for men, 50 g for women (LCD-P)      |                                                                         |                                           |
|                                        |                         |                                   | > LCD + almonds: 55 g for men, 45 g for women (LCD-A)                           |                                                                         |                                           |
| Carbohydrate-restricted Paleolithic-based diet | Randomized crossover trial | 12 subjects with metabolic syndrome | 4-week diet intervention:                                                      | PD-S + PD-Ex: ↑ Glycemia, TG, fasting insulin, insulin resistance, CRP, TNF-α, IL-6, ICAM-1 | Gyorkos et al. (2019)                     |
|                                        |                         |                                   | > carbohydrate-restricted (<50g) Paleolithic-based diet + sedentary activity (PD-S) |                                                                         |                                           |
|                                        |                         |                                   | > PD + high-intensity interval training (PD-Ex)                                |                                                                         |                                           |
| Low-carbohydrate high fat, diet        | Randomised controlled   | 55 obese subjects                 | 12-week diet intervention:                                                      | HFLC: ↑ CRP, TG ↑ adiponectin, HDL                                      | Ruth et al. (2013)                       |
|                                        | trial                   |                                   | > High-fat, low-carbohydrate diet (HFLC) group                                |                                                                         |                                           |
|                                        |                         |                                   | > Low-fat, high-carbohydrate diet (LHFC) group                                |                                                                         |                                           |
| Nutritional ketosis                    | Randomised controlled   | 262 patients with T2DM            | 12-month diet intervention:                                                      | ↑ CRP                                                                   | Bhanpuri et al. (2018)                   |
|                                        | trial                   |                                   | > Nutritional ketosis (NK, n = 262)                                           |                                                                         |                                           |
|                                        |                         |                                   | > Control group, normal diet (n = 87)                                         |                                                                         |                                           |
| Moderate-carbohydrate versus low-fat diet | Randomised controlled trial | 122 overweight and obese adults | 6-month diet intervention:                                                      | LGI vs LF: ↑ fasting insulin, ↑ HOMA                                     | Juanola-Falgarona et al. (2014)          |
|                                        |                         |                                   | > Group 1: moderate-carbohydrate and high-glycaemic index (IG) diet (HGI), n = 37 | No significant differences among groups regarding lipid profiles, inflammatory and metabolic risk markers (IL-6, MCP-1, Leptin, ICAM-1). |                                           |
|                                        |                         |                                   | > Group 2: a moderate-carbohydrate and low-GI diet (LGI), n = 36               |                                                                         |                                           |
|                                        |                         |                                   | > Group 3: a low-fat and high-GI diet (LF), n = 31                             |                                                                         |                                           |
| Low-glycemic-index diet                | Randomised controlled   | 90 subjects                       | 12-week diet intervention:                                                      | LGI + FF vs control: [CRP, TNF-α]                                      | Izadi et al. (2018)                      |
|                                        | trial                   |                                   | > isocaloric control diet (50% of energy from carbohydrate, 35% from fat, 15% from protein) |                                                                         |                                           |
|                                        |                         |                                   | > low-glycemic-index diet (LGI) (60% from carbohydrate, 25% from fat, and 15% from protein) |                                                                         |                                           |

(continued on next page)
6. Polyunsaturated fatty acids in the inflammation hallmark

Literature data mentions two main groups of polyunsaturated fatty acids (PUFAs), of plant or animal origin: omega-3 (n-3) and omega-6 (n-6). The most discussed molecules of each group are α-linolenic acid (ALA) and linoleic acid (LA), respectively. Functionally, notable among the omega-3 fatty acids are the eicosapentaenoic acid (EPA) and the docosahexaenoic acid (DHA) (Calder, 2015), although...
decosapentaenoic acid (DPA) is materializing as an important member of the n-3 family (Kaur et al., 2011). In human diets, the two essential PUFAs, LA, and ALA are usually derived from plant sources (such as seeds, nuts, seed oils and derived products), as only plants synthesize them (Calder, 2011). Linseeds and their oil habitually contain 45–55% of n-3 PUFAs, mainly ALA, whereas soybean or rapeseed oil, and walnuts of plankton and algae consumption and not as a result of endogenous only about 10% ALA (Kris-Etherton et al., 2002).

- docosapentaenoic acid (DPA) is materializing as an important member of the n-3 family (Kaur et al., 2011). In human diets, the two essential PUFAs, LA, and ALA are usually derived from plant sources (such as seeds, nuts, seed oils and derived products), as only plants synthesize them (Calder, 2011). Linseeds and their oil habitually contain 45–55% of n-3 PUFAs, mainly ALA, whereas soybean or rapeseed oil, and walnuts of plankton and algae consumption and not as a result of endogenous only about 10% ALA (Kris-Etherton et al., 2002).

Another important food source of n-3 PUFAs are fatty fish and also other seafood or derived products, known as “fish oils”. All these products contain significant quantities of EPA, DPA and DHA, as a result of plankton and algae consumption and not as a result of endogenous synthesis (Poudyal et al., 2011). Noteworthy, the dominant PUFAs in fish, as well as fish oils, vary between species. For instance, cod liver oil contains more EPA than DHA, whereas tuna oil has a higher content of DHA (Calder, 2012). One portion of fish could bring into diet between 200 and 300 mg n-3 PUFAs, while 1 g of fish oil contains almost 30% EPA and DHA, highlighting the importance of diets including seafood. In the absence of fish or derived products, the daily intake of n-3 PUFAs in most adults is below 200 mg/day (Meyer et al., 2003). As plants produce much more LA than ALA, the former is the most customary PUFA in Western diets (Blasbalg et al., 2011). The daily dietary intake of ALA is 0.5–2 g, while of LA greatly increased in the last 50–60 years, along with a significant change of n-6/n-3 ratio (Calder, 2017), reaching as high as 20 in some Western-type diets (Calder, 2011).

LA and ALA share a common metabolic pathway in animals and humans (Poudyal et al., 2011). LA is metabolised by Δ6-desaturase to γ-linolenic acid (GLA), and later by elongase and Δ5-desaturase to arachidonic acid (ARA), while ALA is converted by the same enzymes into EPA, subsequently to DPA then, finally, to DHA. The rate of transformation from ALA to EPA and later to DHA is affected by several factors such as age, sex, or genetics (Baker et al., 2016). In addition, levels of LA, ALA and DHA are affected by chronic diseases as shown in a study comparing lipid levels between patients with autoimmune diseases and healthy controls (Tsoukalas et al., 2019a).

The conversion of dihomo-gamma-linolenic acid (DGLA) to ARA is regulated by insulin and ARA/EPA ratio is a sensitive marker for insulin resistance, a common denominator of most chronic inflammatory diseases. In a study of healthy adult volunteers AA to EPA ratio and the ARA/dihomo-gamma-linolenic acid (DGLA) significantly changed with age (Tsoukalas et al., 2019b). The conversion of dihomo-gamma-linolenic acid (DGLA) to ARA is regulated by insulin and ARA/EPA ratio is a sensitive marker for insulin resistance, a common denominator of most chronic inflammatory diseases. In a study of healthy adult volunteers AA to EPA ratio and the ARA/dihomo-gamma-linolenic acid (DGLA) significantly changed with age (Tsoukalas et al., 2019b).
membrane phospholipids and have important roles in membrane function, which greatly influences cell activity (Burdge and Calder, 2015). The proportion of PUFAs found in the membrane is dependent on cell type, dietary intake and metabolism (Calder, 2017). For example, in healthy subjects receiving a typical Western diet, the percentages of DHA, EPA, and ARA, in mononuclear cells were 2.5, 0.5 and, respectively, 20%, of total fatty acids (Calder, 2011).

The effects exerted by n-3 PUFAs are arbitrated either by the fatty acid molecules or by their bioactive metabolites from one of the three categories: protectins, resolvins, and maresins. The E-resolvins (such as E1, E2, and E3), are produced from EPA, while the D-series resolvins including D1, D2, D3, D4 and D5, neuroprotectins/protectins (NPDP1/ PD1), and the maresins (MaR1), are biosynthesized from DHA (Dalli et al., 2013; Serhan and Petasis, 2011). The biotransformation of n-3 PUFAs involves the COX and LOX pathways. S-resolvins, S-protectins, and S-maresins are produced from DHA and EPA via LOX pathway, while R-resolvins and R-protectins are derived from aspirin-activated cyclooxygenase 2 or cytochrome P450 metabolic transformation of DHA and EPA (Calder, 2015). In most cell types, ARA is highly predominant and exhibits direct links to inflammatory pathways, since it constitutes the substrate for enzymes such as cyclooxygenase 450, cytochrome P450, cyclooxygenase or lipoxygenase,

6.1. Inflammatory-resolving effects induced by PUFAs

Nowadays, the mechanisms of action by which n-3 PUFAs regulate the inflammatory processes are widely investigated. The suppression of inflammation by n-3 PUFAs is associated with one of the following mechanisms (1) competitive inhibition of n-6 PUFA pathway; (2) modification of cell membrane composition; (3) affecting the formation of rafts or (4) direct anti-inflammatory effect of their bioactive metabolites (resolvins, protectins, and maresins) (Poudyal et al., 2011).

It has been demonstrated that the dietary supplementation with DHA and EPA from fish increases in a dose-response manner the content of DHA and EPA in the cell inflammation-responsible phospholipids (Calder, 2017); increased content of DHA or EPA in different tissues, such as adipose tissue or heart was also observed in correlation with their intake (Calder, 2015) (Fig. 3).

These n-3 PUFAs frequently substitute n-6 PUFAs like ARA, resulting in decreased availability of ARA for eicosanoid synthesis. EPA also inhibits ARA metabolism as a competitive substrate for COX-2, decreasing prostaglandin E2 (PGE2) production. In rats, dietary supplementation with ALA inhibits PG biosynthesis from ARA, while equivalent quantities of ALA and LA decreased up to 40% n-6 PUFAs incorporation in phospholipids (Calder, 2017). Furthermore, Rees et al. observed that a daily EPA intake of 2.7 g or 4.05 g for 3 months decreases the PGE2 production by lipopolysaccharide-stimulated mononuclear cells, while a lower dose of 1.35 g did not. EPA was integrated in a linear dose-dependent manner into mononuclear cell phospholipids and plasma. This study suggested a daily threshold in the range of 1.35–2.7 g EPA for the anti-inflammatory action (Rees et al., 2006).

Besides decreasing production of PGE2, DHA and EPA are also substrates for the biosynthesis of lipid derivatives, but the EPA-derived mediators as series-3 prostaglandins (PGD3) or series-5 leukotrienes are typically less biologically potent, having a lower ability to interact with relevant eicosanoid receptors (Calder, 2015). For example, EPA-derived leukotriene B5 (LTB5) is almost 100 times less active as a leukocyte chemoattractant than ARA-derived LTB4 (Calder, 2017). However, in some cases, EPA-derived mediators have similar potency with ARA-derived mediators. It appears that EPA-derived PGD3 inhibits...
the effect of the ARA-derived PGD2, due to a stronger interaction with the DP1 receptor compared to PGD2 (Wada et al., 2007). In other cases, EPA-derivatized mediators exhibited a similar magnitude of effect (e.g., inhibition of TNF-α production by blood monocytes) (Dooper et al., 2002).

6.2. Molecular targets of PUFAs

There are several pharmacological studies suggesting molecular targets for the anti-inflammatory effects of n-3 PUFAs and their metabolites: PPAR-γ, GPR120, CMKLR1 (known as ChemR23), BLT1 (leukotriene B4 receptor 1), GPR32 and ALX/FPR2 (im, 2012). Thus, resolvin E1 and D1 exhibited a higher affinity for these receptors compared to EPA or DHA. Chem R23 and BLT1 are receptors of resolvin E1, while GPR32 and ALX/FPR2, bind to lipoxin A4 and resolvin D1 with high affinity. GPR120 was reported to be a receptor of EPA and DHA (EC50 ~ 1–10 μM), while ALX/FPR2 to annexin I and lipoxin A4 (Serhan and Petasis, 2011). Furthermore, some studies on GPR120 KO mice suggest that n-3 PUFAs that activate GPR120, interact with β-arrestin 2, and suppress NF-κB activation and macrophage-mediated inflammatory responses (Oh et al., 2010). However, it is important to highlight that the in vivo anti-inflammatory effects of n-3 PUFAs in humans might not only occur at high n-3 PUFA levels, it was demonstrated in vitro that BSA-conjugated n-3 PUFAs are incapable of activating GPR120 (im, 2012).

DHA and EPA are weaker agonists of PPAR-γ (EC50 ~ 10–100 μM), while their oxidized metabolites (such as protectin D1) are much more potent (Yamamoto et al., 2005). Also, ALA or ARA has a similar potency to DHA or EPA for on PPAR-γ, and higher for PPAR-α (Calder, 2015). As PPAR-γ activation reduces inflammatory responses, via the NF-κB pathway, this mechanism could partially explain the anti-inflammatory effects of n-3 PUFAs. Furthermore, n-3 PUFAs were reported to suppress NF-κB activation in a PPAR-γ-independent manner by binding to TLR-4 under certain conditions (im, 2012). Taking into account all these reports, it looks like three mechanisms are employed by n-3 PUFAs to suppress inflammatory signalling via NF-κB: (1) preventing NF-κB nuclear translocation via PPAR-γ activation, (2) interfering with membrane activation of NF-κB via TLR4 and (3) interaction with GPR120 initiating an anti-inflammatory signalling cascade (Calder, 2015).

Resolvin D1 is a potent agonist to GPR32 and ALX/FPR2 (EC50 = 8.8 pM and 1.2 pM), while Resolvin E1 strongly binds to Chem R23 (Kd = 4.5 nM), reducing IL-12 production (Krishnamoorthy et al., 2010) and is a partial agonist to BLT1, so it induces NF-κB activation via BLT1, inhibiting neutrophil migration (Arita et al., 2007). For the other resolvin, protectins or maresins, the molecular targets are not yet identified.

Isolated n-3 PUFAs and their bioactive mediators were extensively examined in animal models of colitis or arthritis or using specific transgenic models. n-3 PUFAs and RvD1, RvDS1, and 25R1 administration proved effective in animal models of colitis, decreasing inflammation and chemically induced colonic damage. The beneficial effects are, in all cases, correlated with the reduction of ARA-derived mediators in the colonic mucosa (Bosco et al., 2013; Charpentier et al., 2018; Gobetti et al., 2017; Marcon et al., 2013). Surprisingly, aspirin-triggered resolvin D1 (AT-RvD1) displayed a stronger anti-inflammatory effect than RvD2 in experimental colitis, through lipoxin A4 receptor (ALX) activation (Bento et al., 2011). Furthermore, n-3 PUFAs as fish oil has shown not just anti-inflammatory effects in peripheral tissues, but several beneficial effects in obesity-induced animal models, such as improved lipid profile, decreased hepatic steatosis and insulin resistance (Bargut et al., 2015; Pimentel et al., 2013).

Indeed, beneficial effects of DHA and EPA in adipose tissue were reported in mice fed a high-fructose diet, including modulating pro- and anti-inflammatory markers and ameliorating adipocyte abnormalities. The effects were significantly higher for DHA compared to EPA (Bargut et al., 2017).

Additionally to anti-inflammatory effects, correlated with down-regulation of IL-6 and TNF-α expression in liver, n-3 PUFAs also exhibited triglyceridemia lowering effects in diabetic rats via modulation of PPAR-α (Devarshi et al., 2013; Ghadge et al., 2016). Additionally, Lee et al. demonstrated that a diet with a high n-6/n-3 PUFAs ratio (~9) induced dysbacteriosis of the gut microbiota in obesity-induced T2DM or high-fat-diet treated rats, while a low ratio (~3) enhanced blood glucose homeostasis (Lee et al., 2019). The outcomes of the most recent animal studies are summarized in Table 5.

6.3. n-3 PUFAs effects in humans

In healthy subjects, different daily doses of EPA and DHA up 1800 mg, administered up to 5 months, showed no significant effects on the CIRP, IL-6, and TNF-α (Asztalos et al., 2016; Plock et al., 2014; Muldoon et al., 2016). A comparable conclusion was drawn by other authors. According to Rangel-Huerta’s meta-analysis, consumption of 900 mg–2000 mg n-3 PUFAs does not change inflammatory biomarkers in healthy subjects (Rangel-Huerta et al., 2012). On the other hand, doses between 1250 and 2400 mg n-3 PUFAs for 4 months lowered inflammation in sedentary and overweight middle-aged and older adults (Kiessell-Glaser et al., 2012). Lp-PLA2, another anti-inflammatory marker was significantly reduced by a high dose of EPA (1800 mg) but not by DHA (Asztalos et al., 2016). Interestingly, only DHA modified the lipid profile by decreasing postprandial triglyceride concentrations and significantly increasing low-density lipoprotein cholesterol, with no significant changes in inflammatory biomarkers (Asztalos et al., 2016).

In elderly subjects, daily supplementation with 2500 mg EPA and DHA, for 8 weeks, significantly reduced the plasma levels of fatty acids, IL-1β, IL-6, and TNF-α (Tan et al., 2018). Similarly, in obese patients who received different doses of combined n-3 PUFAs (380–1290 mg DHA and 360–460 mg EPA) for 2–3 months, the intervention reduced the expression of proinflammatory genes in adipocytes and systemic inflammatory markers vCAM-1, CRP, IL-6, and TNF-α (Itaribi et al., 2012; Polus et al., 2016). Furthermore, other relevant metabolic findings connected with n-3 PUFAs treatment were reported, such as decreasing fasting triglycerides and insulin (Allaire et al., 2016; Polus et al., 2016) or decreasing fasting blood glucose in obese diabetics (Eilulu et al., 2016).

Partially, these results are in line with the modest reduction in waist circumference and body-weight found in a meta-analysis (Bender et al., 2014). The authors indicated that the effect regarding waist circumference reduction by fish intake or fish oil supplementation and might be greater in men than in women. The beneficial effect in overweight and obese adults concerning waist circumference and triglyceridemia was confirmed by two other meta-analyses (Du et al., 2015; Zhang et al., 2017).

As most of the cited trials utilize a mixture of DHA and EPA which may mask the effects of each compound, the individual effects of DHA or EPA in obese patients were also investigated, but the results were inconclusive. A significant reduction in serum IL-18 and adiponectin with DHA than with EPA was observed in one study (Allaire et al., 2016), while no differences between DHA and EPA in the expression of pro-inflammatory genes were observed in another study (Vors et al., 2017).

In patients with impaired glucose metabolism and T2DM in almost all studies, none of the combined EPA and DHA doses had any effect on IL-6, IL-1β, CRP, VCAM, and sICAM (Clark et al., 2016; Mocking et al., 2012; Sawada et al., 2016). Further, no effects on glycated haemoglobin (HbA1c) (Sawada et al., 2016; Wong et al., 2010), insulin (Clark et al., 2016) or lipid profile (Veleba et al., 2015) were found. Only Veleba et al. (2015), observed that HbA1c decreased significantly, and fasting blood glucose increased after n-3 PUFAs treatment for 24 weeks, but no other key findings. An overview of the most recent human studies where the inflammatory biomarkers as a result of PUFAs treatments, were assessed as the main outcome, is summarized in Table 6.
for EPA and DHA consumption has been set at 2000 mg, but higher doses Panel on Dietetic Products, 2010). The upper daily value of acceptable

patients with very high triglyceride levels (AHA) recommends a daily intake of 500 mg high and extremely high fasting-triglyceride levels. The American Heart Adult recommendation is 250 mg/day n-3 PUFAs (EPA and DHA) for adult adults (Flock et al., 2013). The European Food Safety Authority

stock, 2010). The polyphenolic molecules originating from diet are involved as

C57BL/6J mice * IL-17: mRNA expression of Foxp3 (in Fat-1 mouse) Kim et al. (2018)

β IL-1; ↓ TNF; ↑ α Tissue uptake; ↓ lipid peroxidation Fini et al. (2010)

PMN infiltration; ↓ TNF-α; ↓ IL–6; ↓ IL–1β; ↓ mRNA expression of VCAM-1, ICAM-1 Lima-Garcia et al. (2011)

PMN infiltration; ↓ mRNA expression of IL-6, TNFα, IL-1β Ishida et al. (2010)

PMN infiltration; ↓ TNF-α; ↓ IL–6; ↑ mRNA expression of ICAM-1 Marcon et al. (2013)

PMN infiltration; ↓ IL–1; ↑ TNF-α; ↓ IL–6; ↓ mRNA expression of ICAM-1 de Molon et al. (2019)

AT-RvD1

DSS colitis vs TNBS colitis ↑ PMN infiltration; ↓ mRNA expression of Fospx2 (in Fat-1 mouse) Kim et al. (2018)

RvD2

DSS colitis ↑ mRNA expression of VCAM-1, ICAM-1 Lima-Garcia et al. (2011)

RvE1

DSS colitis * TNF-α; ↓ IL–6; ↑ mRNA expression of ICAM-1 Bento et al. (2011)

RvD5

Colagen-induced arthritis No statistical significant effect on TNF-α Bento et al. (2011)

MrR1

DSS colitis vs TNBS colitis ↑ PMN infiltration; ↓ TNF-α; ↓ IL–6; ↑ mRNA expression of ICAM-1 Marcon et al. (2013)

PD1

DSS colitis ↑ PMN infiltration; ↓ IL–1; ↑ TNF-α; ↓ IL–6; ↓ mRNA expression of ICAM-1 de Molon et al. (2019)

6.4. Dietary recommendations of n-3 LC-PUFA

Currently, the recommended daily intake of n-3 PUFAs varies as regarding expert committees, ranging from 250 to 500 mg for healthy adults (Flock et al., 2013). The European Food Safety Authority’s (EFSA) recommendation is 250 mg/day n-3 PUFAs (EPA and DHA) for adult males and non-pregnant females, and supplementation of 100–200 mg/day of DHA in pregnancy (EFSA Panel on Dietetic Products, 2010). For children less than 2 years old, the dietary recommendation corresponds to 100 mg DHA, while for children more than 2 years and in adolescents, the daily recommendation is similar to that for adults (EFSA Panel on Dietetic Products, 2010). The upper daily value of acceptable for EPA and DHA consumption has been set at 2000 mg, but higher doses used in clinical trials did not induce adverse effects (Rangel-Huerta et al., 2012).

There are also some additional recommendations in patients with high and extremely high fasting-triglyceride levels. The American Heart Association (AHA) recommends a daily intake of 500 mg–1000 mg DHA and EPA in patients with borderline levels (150–199 mg/dl), 1000–2000 mg in patients with high levels, and 2000–4000 mg in patients with very high triglyceride levels (>500 mg/dl) (Kris-Etherton et al., 2002). Importantly, further research should be conducted before any definitive daily recommendation or on the routine use of n-3 PUFAs in other chronic inflammatory diseases.

Studies show that n-3 PUFAs do not impact in a positive manner the metabolic profile of healthy subjects and induce variable effect on diabetes mellitus cases (no important effects on inflammation but a constant ability to increase the HDL level); on the other hand, a reduction of inflammation is obese and ageing patients as well as those with metabolic syndrome.

7. Role of polyphenols in countering inflammatory phenomena

Literature data demonstrates that there are approximately 8000 different polyphenolic structures, classified into more than ten classes depending on structural characteristics. Regardless of their differences in chemical behaviour, they are all characterized by having an aromatic core (Kaliora et al., 2006; Morita et al., 2013). The polyphenolic molecules originating from diet are involved as key components in countering inflammation, mitigating oxidative stress and protecting endogenous compounds from oxidative lesions, regulating the metabolism and promoting a protective phenotype, in improving the endothelial function as well as the platelet function, among several other beneficial actions (Kaliora et al., 2006; Morita et al., 2017; Nitulescu et al., 2017, 2019).

Polyphenols are key dietary components extensively studied for their involvement in preventing CVD, comorbidities of metabolic syndrome,
Table 6
Clinical effects induced by PUFAs.

| Intervention | (n) | Main anti-inflammatory findings | Other relevant findings | References |
|--------------|-----|---------------------------------|-------------------------|------------|
| Healthy subjects |     |                                 |                         |            |
| 4-month intervention: |     | [1]TNF-α and [1] IL-6 for both low and high dose groups | [1] n-6:n-3 ratio for both low and high dose groups | Kiecolt-Glaser et al. (2012) |
| > 1.5 g fish oil (1042.5 mg EPA and 174 DHA daily) | 138 |                                 |                         |            |
| > 2.5 g fish oil (2085 mg EPA and 348 mg DHA daily) |     |                                 |                         |            |
| > placebo |     |                                 |                         |            |
| 6-week intervention: |     |                                 |                         |            |
| > 600 mg EPA/day | 121 | No effect on hsCRP, TNF-α, IL-6, VCAM-1, ICAM-1 and fibrinogen | Only High dose EPA ↓ Lp-PLA2; DHA: ↑ TG; ↑ LDL | Asztalos et al. (2016) |
| > 1800 mg EPA/day |     |                                 |                         |            |
| > 600 mg DHA/day |     |                                 |                         |            |
| > placebo |     |                                 |                         |            |
| 18-week intervention:1000 mg EPA + 400 mg DHA/day vs. placebo | 261 | No effect on serum CRP and IL-6 | – | Muldoon et al. (2016) |
| > 300 mg EPA + DHA/day | 125 | No significant effect on IL-6 or CRP; Marginal effect on TNF-α observed at the highest dose (1800 mg) | Higher BCC DHA was associated with lower TNF-α concentrations. | Flock et al. (2014) |
| > 600 mg EPA + DHA/day |     |                                 |                         |            |
| > 900 mg EPA + DHA/day |     |                                 |                         |            |
| > 1800 mg EPA + DHA/day |     |                                 |                         |            |
| > placebo |     |                                 |                         |            |
| 6-week intervention: |     |                                 |                         |            |
| > 360 mg EPA and 600 mg DHA/day vs. control (butter fat) | 55 | [1] inflammatory gene expression in adipose tissue | [1] TG | Itariu et al. (2012) |
| 3-month intervention: |     |                                 |                         |            |
| > 1290 mg DHA/day vs. placebo | 59 | [1] VCAM-1; [1] PECAM-1; [1] hsCRP No effect in IL-6 | [1] TG; [1] jimuslin. | Polus et al. (2016) |
| 10-week intervention: |     |                                 |                         |            |
| > 2700 mg EPA/day | 154 | No difference between EPA and DHA regarding effect on CRP, IL-6, TNFα | – | Allaire et al. (2016) |
| > 2700 mg DHA/day |     |                                 |                         |            |
| > placebo |     |                                 |                         |            |
| 10-week intervention: |     |                                 |                         |            |
| > 2700 mg EPA/day | 154 | EPA: ↑ TRAF3 and PPARα expression DHA: ↑ PPARα and TNFα expression both ↓ CD14 expression | No significant difference between EPA and DHA. | Vors et al. (2017) |
| > 2700 mg DHA/day |     |                                 |                         |            |
| > control (corn oil) |     |                                 |                         |            |
| 12-week intervention: |     |                                 |                         |            |
| > LSM + 600 mg EPA + DHA/day | 29 | LSM & n-3 PUFA ↑ adiponectin in comparison to LSM | No effect on IL6 | Sedláček et al. (2018) |
| > placebo |     |                                 |                         |            |
| Obese patients |     |                                 |                         |            |
| 2-month intervention: |     |                                 |                         |            |
| > 460 mg EPA and 380 mg DHA/day | 64 | [1] inflammatory gene expression in adipose tissue | [1] TG | Ellulu et al. (2016) |
| > control (butter fat) |     |                                 |                         |            |
| 3-month intervention: |     |                                 |                         |            |
| > 360 mg EPA and 600 mg DHA/day vs. placebo | 107 | [1] CRP but similar effects in placebo | [1] HDL and [1] fasting TG; No effect on HbA1c and FBG | Sawada et al. (2016) |
| > 1290 mg DHA/day vs. placebo |     |                                 |                         |            |
| 9-month intervention: |     |                                 |                         |            |
| > 2388 mg EPA + 1530 mg DHA/day vs. placebo | 36 | No effect in IL-1B, IL-6, hsCRP, ICAM and VCAM | No effect on FBG, insulin, HOMA-IR. | Clark et al. (2016) |
| Type 2 diabetes mellitus |     |                                 |                         |            |
| 12-week intervention: |     |                                 |                         |            |
| > 4000 mg (42% EPA + 25% DHA)/day vs. placebo | 91 | No significant effect on CPR | [1] TG; No effect on LDL, HDL, HbA1c | Wong et al. (2010) |
| > 900 mg EPA/day vs. placebo | 24 | No effect on CRP, IL-6 and TNFα | ↑ HDL and ↑ total cholesterol | Mocking et al. (2012) |
| 8-week intervention: |     |                                 |                         |            |
| > 2700 mg EPA + DHA/day vs. placebo | 84 | ↓ IL-2 and ↑ TNFα | None tested | Malekshahi Moghadam et al. (2012) |
| 12-weeks intervention: |     |                                 |                         |            |
| > 1000 mg EPA/day | 60 | No effect on serum CRP and MDA | No effect on body weight, BMI or fat mass | Azizi-Soleiman et al. (2015) |
| > 1000 mg DHA/day |     |                                 |                         |            |
| > placebo |     |                                 |                         |            |
| 24-week intervention: |     |                                 |                         |            |
| > 2800 mg EPA + DHA + 15 mg pioglitazone/day vs. placebo | 60 | No effect on SOD, TBARS, GSSG/GSH | ↑ HbA1c; ↑ FBG | Veleba et al. (2015) |
| > 2800 mg EPA + DHA + placebo/day |     |                                 |                         |            |
| > 5 mg pioglitazone/day |     |                                 |                         |            |
| 3-month intervention: |     |                                 |                         |            |
| > 1000 mg EPA + 1000 mg DHA/day vs. placebo | 74 | No effect on hsCRP, IL-6, TNF-α, ICAM-1, VCAM-1 | No effect on insulin, HbA1c, adiponectin, leptin, and lipid levels | Poreba et al. (2017) |
| > placebo |     |                                 |                         |            |
| Metabolic syndrome |     |                                 |                         |            |
| 90-day intervention: |     |                                 |                         |            |
| > 1800 mg EPA+ 1200 mg DHA + 10 mL extra virgin oil/day | 102 | No effect on CRP | No effect on TG, TC, HDL, FBG, insulin, HOMA-IR | Venturini et al. (2015) |

(continued on next page)
malignancies, etc., all these diseases having an important etiological inflammatory component. For example, a central stage in the expansion of atherosclerosis is dyslipidemia, which together with increased ROS production, forms a pro-inflammatory microenvironment predisposing to endothelial dysfunction. The increased expression of adhesion molecules (VCAM-1, ICAM-1, E-selectin) favours the adherence of monocytes to the endothelium and activation of pro-inflammatory pathways in the vascular wall. Likewise, it is demonstrated that ROS and pro-inflammatory molecules generate a microenvironment predisposing to endothelial dysfunction. The increased expression of adhesion molecules (VCAM-1, ICAM-1, E-selectin) favours the adherence of monocytes to the endothelium and their infiltration within the vascular wall. As a result, of monocyte diapedesis pro-inflammatory molecules are released (TNF-α, IFN-γ, MCP-1), NFκB is up-regulated, interleukins (IL-6 and IL-8) and metalloproteinases (MMPs) are synthesized (Gradinaru et al., 2017, 2018; Hansson and Libby, 2006; Libby, 2012; Libby et al., 2014; Ungurianu et al., 2019).

7.1. Cellular effects

Polyphenols interfere with the inflammatory process in multiple pathways. For example, they alter the enzymatic processes involved in the proliferation and activation of B- and T-cells, as key components of the inflammatory pathway (by inhibiting tyrosine and serine-threonine protein kinases). Likewise, polyphenols blunt the synthesis of pro-inflammatory mediators such as cytokines, chemokines (IL-8, IL-6, TNF-α, VCAM-1 and ICAM-1), and angiogenic factors, NFκB or iNOS. Further, an inhibitory effect on several pro-inflammatory enzymes was reported, such as COX-2, MAPK or protein kinase-C (PKC) (Alvaréz-Suárez et al., 2017; Gasparini et al., 2017; Hussain et al., 2016). Thus, studies performed on macrophages proved that resveratrol inhibited the IFN-γ-induced NO production and down-regulated the IFN-γ inducible genes. In this respect, resveratrol decreased STAT1 activation (an important transcription factor for IFN-γ-induced genes) and hindered JAK2 activation (Chung et al., 2011).

Experimental studies arguing the involvement of polyphenols in mitigating inflammation are either performed on cell line models, animal models or have direct clinical implications. In a study exposing human endothelial cells to the effect of Neurosugae and Primitivo extracts or pure compounds - stilbenes (trans-resveratrol, trans-piceid), hydroxycinnamic acids (p-coumaric, caffeic, and caftaric acids) flavonoids (kaempferol, quercetin, myricetin) – before stimulation with lipopolysaccharide (LPS), an inhibition in the expression of adhesion molecules was demonstrated. The anti-inflammatory effect was sustained by a reduction of VCAM-1, ICAM-1, E-selectin, MCP-1 and macrophage colony-stimulating factor (M-CSF), ROS intracellular levels with a correlated attenuation of NFκB and AP-1 activation. Transresveratrol also significantly reduced the endothelial expression and release of M-CSF. All tested compounds reduced the adhesion of monocytes to stimulated endothelial cells, this being a key element in the development of atherosclerosis (Calabriso et al., 2016). The treatment of CDD-18Gc myoblasts-based cells with red wine extract reduced mRNA levels of ICAM-1, VCAM-1, NFκB, and PECAM-1, induced by LPS the anti-inflammatory mechanism being dependent on miR-126 (Angel-Morales et al., 2012).

Another study tested the effects induced by a mixture of four main catechins found in green tea (epicatechin – EC, epigallocatechin – EGC, epigallocatechin gallate – EGCG, epicatechin gallate – GCG), as well as each one alone, on neutrophils isolated from healthy subjects. The catechin compounds induced anti-inflammatory effect (reduction of IL-1β and IL-6, TNF-α, HOCl synthesis and mioperoxidase), together with the stimulation of antioxidant enzyme activities and Nrf2, along cancer release as well as increased phagocytic capacity, thus proving anti-inflammatory and immunomodulatory actions (Marinovic et al., 2015). In a separate study, EGCG reduced ICAM-1, NFκB and iNOS expressions and reduced ROS levels upon TNF-α-induced inflammation in human retinal pigment epithelial cells. The results suggest the possible therapeutic involvement of EGCG in blocking TNF-α-mediated eye inflammation (Thichanpiang and Wongprasert, 2015). Moreover, in a study evaluating the effect of epicatechin and catechin on arachidonic acid-activated platelets and, respectively, on platelet-HUVEC interaction, the tested compounds induced a reduction of sICAM1, sVCAM1, and sE-selectin levels, as well as an increase of NO bioavailability, proving an anti-inflammatory effect and the ability to counteract endothelial dysfunction, but only when platelets were harvested from peripheral artery disease patients and not from healthy subjects (Carnevale et al., 2014).

Ellagic acid (EA) was tested for its ability to inhibit MIF-induced chemotactic migration of PMBCs, showing a failure to inhibit this response when PMBCs were stimulated with MIP-1α, but high specificity for MIF-induced effect (Sarkar et al., 2015). Chlorogenic acid exerted a dose dependent anti-inflammatory effect showed by the reduction of IL-1β, TNF-α and IL-6 levels as well as the inhibition of NO synthesis and expression of COX-1 and iNOS in LPS-stimulated murine macrophages and microglial cells (Hwang et al., 2014).

An in vitro experiment evaluated the effects induced by various flavonoids on the arachidonic acid release from rat neutrophils; kaempferol, luteolin, quercetin and amentoflavone reduced the

---

**Table 6 (continued)**

| Intervention | (n) | Main anti-inflammatory findings | Other relevant findings | References |
|-------------|-----|--------------------------------|------------------------|------------|
| > 1800 mg EPA + 1200 mg DHA + placebo/day | | | | |
| > 10 mL extra virgin oil/day | | | | |
| > placebo | | | | |
| Inflammatory bowel disease | | | | |
| 8-week intervention: 3400–3600 mg n-3 PUFAs (as salmon)/day | 12 | ↑ n-3 Fatty acids; ↑ n-3:n-6 ratio in plasma and rectal biopsies; No effect on theecal calprotectine | | Grimstad et al. (2011) |
| 90-day intervention: 2000 mg EPA/day | 20 | ↑ IL-10 expression; HES1, SOCS3, and KLF4 | | Prossomariti et al. (2017) |
| 6-month intervention: 1000 mg EPA/day vs.placebo | 60 | No effect on calprotectine | Partially redressed microbiota composition; ↑ecal calprotectine | Scaioli et al. (2018) |

**EPA** – Eicosapentaenoic Acid; **DHA** – Docosahexaenoic Acid; **PG** – Prostaglandins; **LTB** – Leukotriene; **TNF-α** – Tumour Necrosis Factor alpha; **IL** – Interleukin; **CRP** – C-Reactive Protein; **VCAM** – Intercellular Adhesion Molecule; **ICAM** – Vascular Cell Adhesion molecule; **sCRP** – high sensitive C reactive protein; **IL18** – interleukin-1 receptor antagonist protein; **LSM** – lifestyle modification; **NFκB** – nuclear factor-kappa B); **PPAR** – peroxisome proliferator-activated receptor; **TRAF3** – TNF Receptor Associated Factor 3; **Lp-PLA2** – lipoprotein-associated phospholipase A2; **PECAM** – platelet and endothelial cell adhesion molecule; **COX** – cyclooxygenase; **LOX** – lipoxygenase; **TBARS** – thiobarbituric acid substances; **SOD** – superoxide dismutase; **GSH** – glutathione peroxidase; **MDA** – malondialdehyde; **HOMA-IR** – homeostasis model assessment of insulin resistance index; **HES1** – transcription factor HES1; **SOCS3** – suppressor of cytokine signaling 3; **KLF4** – Kruppel-like factor 4; **HbA1c** – Glycated haemoglobin; **RBC** – red blood cell; **BDNF** – Brain-derived neurotrophic factor; **CD14** – cluster of differentiation 14; **NEFA** – Non-esterified fatty acids; **TC** – total cholesterol; **TG** – Triglycerides; **LDL** – low-density lipoproteins; **HDL** – high-density lipoproteins; **FBG** – fasting blood glucose; **LIF** – leukocyte inhibitory factor.

Food and Chemical Toxicology 143 (2020) 111558

D. Margonis et al.

Partially redressed microbiota composition; No effect on theecal calprotectine

**HbA1c** – Glycated haemoglobin; **RBC** – red blood cell; **BDNF** – Brain-derived neurotrophic factor; **CD14** – cluster of differentiation 14; **NEFA** – Non-esterified fatty acids; **TC** – total cholesterol; **TG** – Triglycerides; **LDL** – low-density lipoproteins; **HDL** – high-density lipoproteins; **FBG** – fasting blood glucose; **LIF** – leukocyte inhibitory factor.
inflammatory response and inhibited the activity of β-glucuronidase and lysozyme (Tordera et al., 1994). Furthermore, the positive outcome of Brassica oleracea extracts (water and methanol respectively) for CVD risk were examined; for this purpose, HUVECs were exposed to the extracts (24 h) and then to TNF-α stimulation. Exposure to the extracts from Brassica oleracea significantly reduced the TNF-α induced expression of E-selectin, ICAM-1 and VCAM-1 (Kuntz and Kunz, 2014). Another study demonstrated the capacity of extracts from Mango (Mangifera indica L.) to counteract TNF-α effects on HUVECs, through the inhibition of IL-6, IL-8, COX-2 and ICAM-1, while restoring the expression of eNOS usually down-regulated by TNF-α (Mura et al., 2015). Interestingly, in an animal model, for example, supplementation of standard chow with cacao phenolic compounds in apolipoprotein E-deficient mice, lead to an anti-inflammatory effect justified by a reduction of VCAM-1 and ICAM-1 expressions, a decrease of oxidative stress markers and a reduction of cholesterol accumulation in plaque compared to control (Natsume and Baba, 2014). Likewise, propolis (green, red or brown) treatment induced a reduction of MCP-1, VCAM, PECAM, FGF, PDGF, VEGF, MMP-9 and upregulated tissue inhibitor of metalloproteinases 1 (TIMP-1) in initial atherosclerotic lesions in LDL receptor gene knockout mice fed a diet (Daleprane et al., 2012).

7.2. Anti-inflammatory potential of polyphenols in humans

The anti-inflammatory effects induced by polyphenols in human studies with dietary interventions and weight related outcomes are heterogeneous, as summarized from recent literature (Table 7). Thus, in a clinical study with double-blind, randomized, cross-over design, the effect of a commercially available polyphenols rich extract was tested, the study including patients having more than two metabolic risk factors. Results showed a reduction of MCP-1 and MIF, but not of other markers of CVD risk (CRP, IL-6, HDL, adiponectin and oxidized LDL) (Broekhuizen et al., 2011). In a separate clinical study with cross-over design, overweight patients consumed a high-carbohydrate, moderate-fat meal supplemented with strawberry/placebo juice. The anthocyanin supplementation blunted the postprandial inflammatory response (reduced CRP level) induced by the high fat diet and reduced the postprandial insulin response (Edirisinghe et al., 2011). Furthermore, a double-blind study focused on hypercholesterolemia subjects, receiving a purified anthocyanin mixture, resulted in a reduction of their CRP, sVCAM-1 and IL-1β levels. Similar results were obtained for HepG2 and porcine iliac artery endothelial cells exposed to the same purified anthocyanin mixture (reduction of LPS-induced VCAM-1 secretion) (Zhu et al., 2013). Patients with early atherosclerosis, received simple or EGCG-enriched olive oil. Independent of EGCG addition, olive oil reduced inflammatory markers and endothelial dysfunction (sICAM, white blood cells, monocytes, lymphocytes and platelets) (Jennings et al., 2014). The effects of grape seed extract on pre-hypertension patients were tested. Results of the study in question, showed a reduction of blood pressure (both systolic and diastolic), with improved fasting insulin and insulin sensitivity after 6 weeks of supplementation, but no significant change in sICAM-1 plasma concentration (Park et al., 2016). Furthermore, in a single blinded crossover trial including patients with

| Design | Population | Type of intervention | Inflammatory outcome | Reference |
|--------|------------|----------------------|----------------------|-----------|
| Randomised, double-blind, cross-over study | 34 subjects with two or more metabolic risk factors | 4-week intervention: 500 mg polyphenols/day vs. placebo high-carbohydrate, moderate-fat meal together with a strawberry beverage (SB) or placebo | ↓MCP-1 and MIF, unchanged levels of HDL, adiponectin, CRP; ↑SB; ↓CRP and postprandial insulin | Broekhuizen et al. (2011) |
| Cross-over study | 24 overweight adults | 150 hypercholesterolemic subjects | 24-week intervention: 640 mg purified Anthocyanin/day | ↑CRP, sVCAM-1 and IL-1β | Zhu et al. (2013) |
| Randomised, double-blind | 52 patients with early atherosclerosis, 36 pre-hypertension patients, randomized to control or treatment groups | 4-month intervention: 30 mL olive oil or 30 mL of EGCG-supplemented olive oil | ↓IL-12, ↑ICAM, white blood cells, monocytes, lymphocytes and platelets | Widmer et al. (2013) |
| Single-centre, randomised, two-arm, double-blinded, placebo-controlled study | 38 patients with untreated mild hypertension | 6-month intervention: grape seed extract, 150 mgx2/day | ↓JBP (SBP, DBP), ↑fasting insulin and insulin sensitivity | Park et al. (2016) |
| Single blinded crossover trial | 38 subjects with metabolic syndrome | 8-week intervention: 300 mL/day cold-pressed 100% chokeberry juice and 3 g/day chokeberry powder | No change of sICAM-1 (IL-10 and TNF-α) | Loo et al. (2016) |
| Randomized, double-blind, placebo-controlled clinical trial | 50 hyperlipidemic patients | 4-week intervention: V. arctostaphylos fruit extract x2/day | No effects on HDL and CRP; ↑total cholesterol, LDL-C, TG, MDA | Soltani et al. (2014) |
| Placebo controlled study | 20 study subjects and 19 placebo | 4-week intervention: 361 mg polyphenols and 120 mg vitamin C x2/day | No significant effects on apolipoproteins, adiponectin, CRP, ICAM-1, E-Selectin or t-PA | Mullan et al. (2016) |
| Placebo controlled study | 16 trained cyclists | 7-day intervention: 30 mL of Monomerecy tart cherry concentrate x 2/day | ↓lipid hydroperoxides, IL-6 and hsCRP | Bell et al. (2014) |
| Double-blind crossover study | 49 healthy male subjects with APOE genotype | 8-week intervention: 150 mg/day quercetin or placebo (3 phases, three-week washout periods) | ↓waist circumference and postprandial SIBP, moderately increased levels of TNF-α, ↓IL6 production | Peufler et al. (2013) |
| Randomised, double-blind, placebo-controlled, cross-over trial | 18 healthy volunteers | One-time administration of 51 mg of oleuropeine | ↓Higher anthocyanin and flavone intake were associated with significantly lower peripheral insulin resistance | Lockyer et al. (2015) |
| Cross-sectional study | 1997 females | Frequency questionnaires assessment of total intake of flavonoids | Higher anthocyanin intake was also associated with lower CRP concentrations | Jennings et al. (2014) |
| Randomized, controlled dietary study | 27 subjects with metabolic syndrome | 400 g fresh bilberries/days vs. control diet | Higher anthocyanin-rich intake was associated with lower insulin and inflammation | Kolehmainen et al. (2012) |
untreated mild hypertension, cold-pressed chokeberry juice and dried chokeberry powder induced a reduction of IL-10 and TNF-α levels (Loo et al., 2016).

On the other hand, there are studies that do not confirm the positive effects of natural compounds on inflammatory markers regarding cardiovascular risk, especially on CRP, even if they prove to yield other beneficial outcomes (for example, on LDL). Thus, Soltani et al. examined the effects of a Vaccinium arctostaphylos fruit extract on hyperlipidemic adult patients and even if no significant effects were observed regarding HDL and CRP, a significant reduction of total cholesterol, LDL, triglycerides and malondialdehyde (MDA) levels was obtained (Soltani et al., 2014). Furthermore, Mullan et al. showed that administering a vitamin C and polyphenol-rich beverage didn’t induce a reduction of metabolic or inflammatory markers (apolipoproteins, CRP, IGAM-1, E-selectin) (Mullan et al., 2016).

Results regarding the effect of polyphenols on inflammation were obtained not only in metabolically impaired patients, but also in healthy subjects. Thus, in a placebo-controlled study, the effect induced by Monmorcley tart cherry concentrate on the inflammatory and redox status markers in subjects simulating road cycle racing was examined. Trained cyclists received the concentrate or placebo for 7 days, after which their oxidative stress and inflammatory markers (IL-6 and CRP) were reduced, highlighting the ability of the tested extract to improve the stress response in physical exercise conditions (Bell et al., 2014).

Furthermore, in a study with a crossover, double-blind design, 49 healthy males with APOE genotype received 150 mg/day quercetin or placebo for 8 weeks, in three phases, separated by three-week washout periods. Quercetin administration led to a decrease of waist circumference and postprandial systolic blood pressure, as well as a moderately increased levels of TNFα (Pfeuffer et al., 2013). In a separate study with cross-over, double-blind, randomized, placebo-controlled design including 18 healthy subjects, the effect of oleuropeine (51 mg) on a single occasion was tested. Blood of the subjects was collected and cells were stimulated with LPS, showing a significant decrease of IL-8 production (Lockyer et al., 2015).

Flavonoid-rich products have also been discussed for their beneficial effect on insulin resistance-related metabolic complications possibly via the upregulation of genes involved in insulin sensitivity (Engin et al., 2018). In a recent review, the beneficial effect of flavonoid-rich products in a cross-sectional study including 1997 females aged 18–76 years, the correlation between the total flavonoid intake as well as their subclasses (assessed from food questionnaires) and insulin resistance/inflammation was evaluated. Results showed higher anthocyanin and flavone intake were associated with significantly lower peripheral insulin resistance and CRP concentrations (Jennings et al., 2014). In a randomized controlled dietary study, results showed that consuming a high anthocyanins diet is associated with the reduction of CRP, IL-6, IL-12, and LPS concentrations indicating a positive effect on the long term cardiometabolic risk (Kolehmainen et al., 2012).

According to literature data, polyphenols blunt the inflammatory response in clinical setting, thus reducing the cardio-vascular risk factors for hypertensive, obese or diabetes mellitus patients. Positive effects on inflammation and redox stress markers were also obtained in healthy subjects and, moreover in trained athletes, who seem to benefit from the polyphenols intake (Soltani et al., 2014; Bub et al., 2019).

In an 8-week randomized controlled dietary study on overweight patients, a combined diet of high polyphenols and marine PUFA diets showed beneficial, although non-additive effects on plasma triglycerides. Also, the reduction in oxidative stress (measured by urinary 8-isoprostanate) was observed, probably as an effect of polyphenols. A negative interaction between PUFA:s and polyphenols was observed for some variables (chylomicron cholesterol and apo B-48 in large VLDLs), which suggest a possible kinetic interaction between PUFA:s and polyphenols (Annuzzu et al., 2014). This kinetic finding is also in line with some preclinical data that suggested that dietary polyphenols interact with the metabolism of n-3 PUFA:s and increase blood EPA and DHA level (Toulektsian et al., 2011).

Recently, in a three monocentric, parallel-arm, double-blind, randomised, dietary intervention trial, 250 mg DHA and 320 mg grape anthocyanins administered as bioactive-enriched foods, for 4 weeks, had positive effects on serum triglyceride or HDL levels (Bub et al., 2019). These results are partially in line with a later cross-sectional analysis in the Korean population that suggested beneficial effects exhibited only in men by high amounts of proanthocyanidins or n-3 PUFA:s on HDL levels. In addition, n-3 PUFA:s intake increased polyphenols uptake (Ahn et al., 2020).

In conclusion, large-scale cohort studies with a combined diet PUFAs + polyphenols are needed to confirm the limited available data and to investigate possible additive effects.

8. Metabolic disorder and inflammation in COVID-19

Metabolic disarray and inflammation are important factors in the pathogenesis of acute diseases. COVID-19, severe respiratory disease, is an adverse clinical outcome of the ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic (Doucea et al., 2020; Goumenou et al., 2020; Shi et al., 2020), and has recently been correlated to obesity-dependent inflammation (Petrakis et al., 2020). Indeed, in its most severe form, it entails a bilateral interstitial pneumonia requiring intensive care unit (ICU) ventilation support and has concomitant high mortality rate due to and multi-organ failure. Clinical reports have demonstrated that the most common comorbidities are CVD, hypertension and T2DM, age also being an important risk factor (Grasselli et al., 2020; Zhou et al., 2020). Lifestyle-associated factors, such as smoking, have also been associated with rapid disease progression (Farsalinos et al., 2020; Mesnage et al., 2020; Tsatsakis et al., 2020). A recent US study indicates that obesity is an underappreciated risk factor for COVID-19 (Kass et al., 2020). The authors found, in a cohort of 265 hospitalized patients, that age and the body-mass index (BMI) were inversely correlated with risk, hence indicating that younger obese patients were more likely to be admitted to hospital. Kass et al. concluded that a higher prevalence of obesity in each population will result in a higher COVID-19 incidence in younger individuals than previously reported. In addition to a mechanical impediment of ventilation, obesity was correlated with lower immune response to viral infection (Honce and Schultz-Cherry, 2019). Moreover, besides obesity, metabolic disarray and inflammation were suggested to contribute to COVID-19 pathogenesis (Petrakis et al., 2020). Indeed, specific fat-resident regulatory T cells (Treg) and enhancement of TH17 (T-cell sub-lineage)-biased immunity (Poutahidis et al., 2013; Winer et al., 2009) could be positively correlated to COVID-19 prevalence and increased mortality risk in obese individuals (Petrakis et al., 2020; Skalny et al., 2020). The “obese” pattern of immune cells subtypes was correlated to increased secretion of pro-inflammatory mediators including IL-6, IL-23/IL-17, TNF-α and macrophage inflammatory protein-1α (Sumarac-Dumanovic et al., 2009). Importantly, these inflammatory mediators were proved to disrupt tight junctions of the respiratory epithelium, which facilitates pathogen entry (Wittekindt, 2017).

COVID-19 is impacting to a greater extent the patients having underlying metabolic impairments (diabetes mellitus and/or obesity), as WHO is pointing out. On the other hand, increased levels of inflammatory markers cytokines with pro-inflammatory outcomes constitute predictors of adverse outcome in COVID-19 patients (Skalny et al., 2020).

Thus, reducing the inflammatory pathways, through the long-term employment of lifestyle changes (dietary measures, smoking cessation,
9. Conclusions

Diet can play a major part in regulating various cellular pathways, as one is simultaneously and continually exposed to a myriad of ingested substances, which, in their minute doses can yield important long-term effects and influence the development of certain maladies, with their cumulative effects still being underestimated. Real-life risk simulation (RLRS) strategies are powerful tools for assessing not only the toxicological implications of joint effects for several molecules, but also their collective beneficial role as nutraceuticals in our diet intake. These kinds of analyses are important, as studies which separately assess the cellular and metabolic effects of certain compounds can posit their detrimental or protective actions and their potency, and thus can lead to erroneous conclusions regarding their long-term habitual consumption in lower, non-pharmacological doses, but alongside numerous other chemicals (Hernandez et al., 2020; Margina et al., 2019). This type of approach will certainly play an important part in one of the most important health struggles nowadays, the prevention of NCD, and could prove itself beneficial even in the context of the present viral outbreak, since inflammation is the key component of the severe phenomena associated with the COVID-19 respiratory complications. There is an intense need for RLS studies integrating diet with inflammation in order to evaluate if the usual components of normal diet could contribute to regulating the immune response and reduce the sensitivity to complications.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Aggarwal, B.B., 2009. Inflammation, a silent killer in cancer is not so silent! Curr. Opin. Pharmacol. 9, 347–350.
Ahn, S., Sun, J., Song, H., 2020. Association of total flavonoid intake with hype-HDL-cholesterolemia among Korean adult: effect modification by polyunsaturated fatty acid intake. Nutrients 12.
Aliaghaizadeh, A., Dehghan, P., Gargari, B.P., Aghari-Jafarabadi, M., 2015. Resistant dextrin, as a prebiotic, improves insulin resistance and inflammation in women with type 2 diabetes: a randomised controlled clinical trial. Br. J. Nutr. 113, 321–330.
Alaire, J., Couture, P., Leclerc, M., Charest, A., Marin, J., Lestel-Robin, A., Anguillet, L., Viner, M., 2014. Impact of consuming a virgin olive oil or nuts within a Mediterranean diet on DNA methylation in peripheral white blood cells within the PREMEDIT-Navarra randomized controlled trial: a role for dietary lipids. Nutrients 10.
Ampatzoglou, A., Williams, C.L., Atwal, K.K., Maidens, C.M., Ross, A.B., Thielecke, F., Slattery, M.L., Bingham, S.A., 2016. Adherence to Mediterranean diet is associated with methylation changes in inflammation-related genes in peripheral blood cells. J. Physiol. Biochem. 73, 455–455.
Aole, Mohammad Zadeh, M., Kargarfard, M., Marandi, S.M., Habibi, A., 2018. Diets along with interval training regimes improves inflammatory anti-inflammatory condition in obesity with type 2 diabetes subjects. J. Diabetes Metab. Disord. 17, 253–267.
Asztalos, J.B., Gleason, J.A., Sever, S., Giedrig, R., Asztalos, B.F., Horvath, K.V., Dansinger, D.L., Lamon-Fava, S., Schaefer, E.J., 2016. Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: a randomized clinical trial. Metabolism 65, 1636–1645.
Azizi, Soleimani, F., Jazayeri, S., Ghanbari, S., Razavi, H., Heidari, L., Vafa, M.R., Gohari, M.R., 2013. Effects of pure eicosapentaenoic and docosahexaenoic acids on oxidative stress, inflammation and body fat mass in patients with type 2 diabetes. Int. J. Prev. Med. 4, 922–928.
Baker, E.J., Miles, E.A., Burdge, G.C., Yaqoob, P., Calder, P.C., 2016. Metabolism and functional effects of plant-derived omega-3 fatty acids in humans. Prog. Lipid Res. 64, 30–56.
Bargut, T.C., Mandirar-de-Lacerda, C.A., Aguilera, M.B., 2015. A high-fish-oil diet prevents adiposity and modulates white adipose tissue inflammation pathways in mice. J. Nutr. Biochem. 26, 960–969.
Bargut, T.C., Santos, L.P., Machado, D.G.L., Aguilera, M.B., Mandirar-de-Lacerda, C.A., 2017. Eicosapentaenoic acid (EPA) vs. Docosahexaenoic acid (DHA): effects in epididymal white adipose tissue of mice fed a high-fructose diet. Prostaglandins Leukot. Essent. Fatty Acids 123, 124–124.
Barrea, L., Marzullo, P., Muscogiuri, G., Di Somma, C., Scaccia, M., Orio, F., Aimaretti, G., Colao, A., Savastano, S., 2018. Source and amount of carbohydrates in the diet and inflammation in women with polycystic ovary syndrome. Nutr. Res. Rev. 31, 291–301.
Basil, M.C., Levy, B.D., 2016. Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat. Rev. Immunol. 16, 51–67.
Basu, A., Kurien, B.T., Tran, H., Byrd, B., Maher, J., Schell, J., Masek, E., Barrett, J.R., Lyons, T.J., Betts, N.M., Hall Scofield, R., 2018. Strawberries decrease circulating levels of tumor necrosis factor and lipid peroxides in obese adults with knee osteoarthritis. Food Funct. 9, 6229–6236.
Bedard, A., Lamarche, B., Corneau, L., Dodin, S., Lemieux, S., 2015. Sex differences in the adoption improves metabolic, oxidative, and inflammatory abnormalities in Algerian metabolic syndrome patients. Horm. Metab. Res. 47, 264–274.
Bell, P.G., Walsh, I.H., Davison, G.W., Stevenson, E., Howatson, G., 2014. Montmorency cherries reduce the oxidative stress and inflammatory responses to repeated days high-intensity stochastic cycling. Nutrients 6, 929–942.
Bender, N., Portmann, M., Heg, Z., Hofmann, K., Zwahlen, M., Egger, M., 2014. Fish or chicken intake are associated with low-grade chronic inflammation in post-menopause: a cross-sectional study. Eur. J. Clin. Nutr. 68, 908–919.
Angel-Morales, G., Norato, G., Mertens-Talcott, S., 2012. Red wine polyphenolics reduce the expression of inflammation markers in human colon-derived CD180 myeloid cell line. Food Chem. 126, 745–752.
Annucci, G., Zappeti, N., Costabile, G., Giacca, R., Mangione, A., Anniballi, G., Vitale, M., Vetran, C., Cipriano, P., Dela Corte, G., Pasanisi, F., Riccardi, G., Nivelone, A.A., 2014. Diets naturally rich in polyphenols improve fasting and postprandial dyslipidemia and reduce oxidative stress: a randomized controlled trial. Am. J. Clin. Nutr. 99, 463–471.
Aouadi, M., Tenceroova, M., Vangala, P., Yaw, J.C., Nicoloro, S.M., Amanu, S.S., Cohen, J.L., Czech, M.P., 2013. Gene silencing in adipose tissue macrophages regulates whole-body metabolism in obese mice. Proc. Natl. Acad. Sci. U. S. A. 110, 8278–8283.
Arita, M., Ohira, T., Sun, Y.P., Elvang, S., Chiang, N., Serhan, C.N., 2007. Resolving E1 specifically inactivated by leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol. 178, 3912–3917.
Arpon, A., Milagro, F.I., Razquin, C., Corella, D., Estruch, R., Marti, A., Martinez-Gonzalez, M.A., Ros, E., Salas-Salvado, J., Rieuze-Boj, J.I., Martinez, J.A., 2017. Impact of consuming extra-virgin olive oil or nuts within a Mediterranean diet on DNA methylation in peripheral white blood cells within the PREMEDIT-Navarra randomized controlled trial: a role for dietary lipids. Nutrients 10.
Arpon, A., Rieuze-Boj, J.I., Milagro, F.I., Marti, A., Razquin, C., Martinez-Gonzalez, M.A., Corella, D., Estruch, R., Casas, R., Fito, M., Ros, E., Salas-Salvado, J., Martinez, J.A., 2016. Adherence to Mediterranean diet is associated with methylation changes in inflammation-related genes in peripheral blood cells. J. Physiol. Biochem. 73, 455–455.
Angel-Morales, G., Norato, G., Mertens-Talcott, S., 2012. Red wine polyphenolics reduce the expression of inflammation markers in human colon-derived CD180 myeloid cell line. Food Chem. 126, 745–752.
D. Margini et al.

Food and Chemical Toxicology 143 (2020) 111558

Hussain, T., Tan, B., Yin, Y., Blachier, F., Tomsou, M.C., Rahu, N., 2016. Oxidative stress and inflammation: what polyphenols can do for us? Oxid. Med. Cell. Longev. 2016, 7529727.

Hwang, S.J., Kim, Y.W., Park, Y., Lee, H.J., Kim, K.W., 2014. Anti-inflammatory effects of chlorogenic acid in lipopolysaccharide-stimulated RAW 264.7 cells. Inflamm. Res. 63, 83–90.

Hynes, R.O., 2009. The extracellular matrix: not just a pretty fibril. Science 326, 1216–1219.

Im, D.S., 2012. Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs. Prog. Lipid Res. 51, 433–438.

Ishida, T., Yoshida, M., Arita, M., Nishitani, Y., Ishikado, A., Arima, H., Nakao, K., Nakagawa, F., Nikami, F., Sekine, O., Nemoto, K., Suwa, M., Matsumoto, M., Miura, K., Makino, T., Ugi, S., Maegawa, H., 2017. Fiber-rich diet with brown rice improves endothelial function in type 2 diabetes mellitus: a randomized controlled trial. PLoS One 12, e0197869.

Kohukako, S., Lajosy, A.D., Ramsey, K.M., Estrada, C., Josha, C., Kobayashi, Y., Turek, F., W. Bass, J., 2007. High-fat diet disrupts behavioral and molecular circadian rhythms in mice. Cell Metab. 6, 414–421.

Kolemanian, M., Mykkanen, O., Kirjavainen, P.V., Leppanen, T., Moilanen, E., Adhikari, M., Laksenon, D.E., Halikainen, M., Puuponen-Pimia, P., Pelikunen, L., Mykkanen, H., Gylling, H., Postonen, K., Torronen, R., 2012. Bilberries reduce low grade inflammation in individuals with features of metabolic syndrome. Mol. Nutr. Food Res. 56, 1501–1511.

Kondo, K., Morino, K., Nishiyama, S., Arita, H., Nakao, K., Nakagawa, F., Nikami, F., Sekine, O., Nemoto, K., Suwa, M., Matsumoto, M., Miura, K., Makino, T., Ugi, S., Maegawa, H., 2017. Fiber-rich diet with brown rice improves endothelial function in type 2 diabetes mellitus: a randomized controlled trial. PLoS One 12, e0197869.

Kris-Etherton, P.M., Harris, W.S., Appel, L.J., Committee, A.H.A.N., 2002. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106, 2747–2757.

Krishnamoorthy, S., Recchietti, A., Chiang, N., Yacobain, S., Lee, C.H., Yang, R., Petasis, N.A., Serhan, C.N., 2010. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. U.S.A. 107, 1666–16650. Krommacka, A.B., Salo, B.J., Banik, K., Harsha, C., Prasad, S., Gupta, S.C., Bhat, C., Aggarwal, B.B., 2018. Chronic diseases, inflammation, and spices: how are they linked? Transl. Med. 16, 14.

Kunz, S., Kunz, C., 2014. Extracts from Brasica oleracea l. conv. asepa var. asepa inhibit TNS-alginate induced neutrophil adhesion in vitro under flow conditions. Food Funct. 5, 1082–1090.

Lankinen, M., Unitowa, M., Schwab, U., 2019. Nordic diet and inflammation-A review of observational and intervention studies. Nutrients 11.

Lelgie, S.C., Yu, S.H., Lin, Y.C., Huang, S.Y., 2019. A high linoleic acid diet exacerbates metabolic responses and gut microbiota dysbiosis in obese rats with diabetes mellitus. Food Funct. 10, 786–798.

Li, X., Zhao, Y., Chen, C., Yang, L., Lee, H.H., Wang, Z., Zhang, N., Kolomlin, M.G., Am, Z., Ge, X., Scheer, P.E., Sun, K., 2020. Critical role of matrix metalloproteinase 14 in adipose tissue remodeling during obesity. Mol. Cell. Biol. 40.

Liang, Z., Xu, Y., Wen, X., Nie, H., Hu, T., Yang, X., Chu, X., Yang, J., Deng, X., He, J., 2016. Rosmarinic acid attenuates airway inflammation and hyperresponsiveness in a mouse model of asthma. Allergy 71, 1194–1201.

Libby, P., 2012. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32, 2045–2051.

Libby, P., Tabas, I., Friedman, G., Fisher, E.A., 2014. Inflammation and its resolution as determinants of acute coronary syndromes. Circ. Res. 114, 1867–1879.

Lima-Garcia, J.F., Dutra, R.C., da Silva, K., Motta, E.M., Calixto, J.B., 2016. Mediterranean diet cools down the inflammatory milieu in type 2 diabetes: the Nordic diet or the ketogenic diet? Curr. Opin. Endocrinol. Diabetes Obes. 23, 1896–1900.

Liao, J., Lin, C.H., Yu, S.H., Lin, Y.C., Huang, S.Y., 2019. A high linoleic acid diet exacerbates metabolic responses and gut microbiota dysbiosis in obese rats with diabetes mellitus. Food Funct. 10, 786–798.

Lin, C.H., Lee, S.H., Lin, Y.C., Huang, S.Y., 2019. A high linoleic acid diet exacerbates metabolic responses and gut microbiota dysbiosis in obese rats with diabetes mellitus. Food Funct. 10, 786–798.

Liu, X., Zhao, Y., Chen, C., Yang, L., Lee, H.H., Wang, Z., Zhang, N., Kolomlin, M.G., Am, Z., Ge, X., Scheer, P.E., Sun, K., 2020. Critical role of matrix metalloproteinase 14 in adipose tissue remodeling during obesity. Mol. Cell. Biol. 40.

Liu, X., Zhao, Y., Chen, C., Yang, L., Lee, H.H., Wang, Z., Zhang, N., Kolomlin, M.G., Am, Z., Ge, X., Scheer, P.E., Sun, K., 2020. Critical role of matrix metalloproteinase 14 in adipose tissue remodeling during obesity. Mol. Cell. Biol. 40.
Nutrients factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients. Singapore Med. J. 53, 615–619.

Marcora, S.M., Bento, A.A., Buxa, M.A., D.F., Calixto, J.B., 2013. Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis. J. Immunol. 191, 4288–4298.

Margaret, D., Ilie, M., Gradinaru, D., 2012. Quercetin and epigallocatechin gallate induce in vitro a dose-dependent anti-inflammatory and hypoproliferating effect on the cell membrane of human mononuclear blood cells. Int. J. Mol. Sci. 13, 4839–4859.

Margaret, D., Nituşescu, G.M., Ungureanu, A., Mesnage, R., Goumenou, M., Sărătian, D.A., Aşchen, M., Spandasidou, D.A., Renieri, E.A., Hernandez, A.F., Tsatsakis, A., 2019. Overview of the effects of chemical mixtures with endocrine disrupting activity on the context of real-life risk simulation (RLRS): an integrative approach (Review). World Acad. Sci. J. 15, 157–164.

Martins-Barbosa, M.P., Moreira, A.R., Otton, R., 2015. Green tea catechins alone or in combination alter functional parameters of human neutrophils via suppressing the activation of TLR4/NF-kB p65 signal pathway. Toxicol. Vitro 29, 1766–1778.

Marques-Rocha, J.J., Milagro, F.I., Manego, M.L., Zulea, M.A., Bresan, J., Martinez, J., Martinez, J. A., 2016. Expression of inflammation-related miRNAs in white blood cells from subjects with metabolic syndrome after 8 wk of following a Mediterranean diet-based weight loss program. Nutrition 32, 48–55.

Martinez-Gonzalez, M.A., Toledo, E., Aros, F., Miol, M., Corella, D., Salas-Salvado, J., Ros, E., Covas, M.I., Fernandez-Crehuet, J., Lapetra, J., Munoz, M.A., Fito, M., Serra-Majem, L., Pinto, X., Lamuela-Raventos, R.M., Sorli, J.V., Babio, M., Buil-Cosiales, P., Ruiz-Gutierrez, V., Estruch, R., Alonso, A., Investigators, P., 2014. Extravirgin olive oil consumption reduces risk of arterial stiffness: the PREDIMED (Prevenzione con Dieta Mediterranea) trial. Circulation 130, 18–26.

Martucci, M., Ostani, R., Biondi, F., Bellavista, E., Fabbrì, C., Bertarelli, C., Salvioni, S., Capri, M., Franceschi, C., Santoro, A., 2017. Mediterranean diet and inflammation within the framework paradigm. Nutr. Rev. 75, 442–455.

Mars, E., Salmena, L., Zandi, K., Zelcer, A., Mor, T., 2008. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin. Chem. 54, 1476–1484.

Mayer, H.L., Thomas, C.J., Tierney, A.C., Kucianski, T., George, E.S., Ruiz-Canela, M., Mayr, H.L., Thomas, C.J., Tierney, A.C., Kucianski, T., George, E.S., Ruiz-Canela, M., 2012. Quercetin and epigallocatechin gallate induce increased systemically in human type 2 but not type 1 diabetes independently of inflammation, diet composition and health: current research evidence and its evidential basis supporting health benefits from a decreased exposure to pesticides and other dietary contaminants (Review). Food and Chemical Toxicology 143 (2020) 111558.
Rees, D., Miles, E.A., Banerjee, T., Wells, S.J., Roynette, C.E., Wahle, K.W., Calder, P.C., Poll, A., Minculescu, C., Nimigean, V., Badita, D., Balaceanu, R., Paun, D., Moraru, S., Rallidis, L.S., Kolomvotsou, A., Lekakis, J., Farajian, P., Vamvakou, G., Dagres, N., Prossomariti, A., Scaioli, E., Piazzi, G., Fazio, C., Bellanova, M., Biagi, E., Candela, M., Roager, H.M., Vogt, J.K., Kristensen, M., Hansen, L.B.S., Ibrugger, S., Maerkedahl, R.B., Rajkumar, R.P., 2020. Ayurveda and COVID-19: where psychoneuroimmunology and the

Soutani, R., Assouti, M., Nikitovic, D., Krasagakis, K., Karamanos, N.K., Tzanakakis, G.N.,

Sifaki, M., Assouti, M., Nikitovic, D., Krasagakis, K., Karamanos, N.K., Tzanakakis, G.N.,

Sharma, M., Kaur, R., Kaushik, K., Kaushal, N., 2019. Redox modulatory protective

Sanak, M., Childs, C.E., Calder, P.C., Dembinska-Kiec, A., 2016. Omega-3 fatty acid

Rouhani, M.H., Kelishadi, R., Hashemipour, M., Esmaillzadeh, A., Surkan, P.J., Rosenbaum, M., Hall, K.D., Guo, J., Ravussin, E., Mayer, L.S., Reitman, M.L., Smith, S.R.,

Pimentel, G.D., Lira, F.S., Rosa, J.C., Oller do Nascimento, C.M., Oyama, L.M., Harumi

Pozzilli, P., Galli, S., Zaccagni, S., Colombo, E., Azzaroli, G., Pumiglia, A., Lattuada, G.,

Perrone, F., Montowik, M., Sianiark, A., Golebiowska-Wiatrak, R., Malinzowski, K.P.,

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.

Peyrin-Biroulet, L., Pajares, P., Dayer, J.M., Teyssandier, F., Bousquet, J., 2017. Omega-3 fatty acids and the resolution of chronic inflammation. Nat. Rev. Immunol. 17, 495–508.
Tosti, V., Bertolzi, B., Fontana, L., 2018. Health benefits of the mediterranean diet: metabolic and molecular mechanisms. J. Gerontol. A Biol. Sci. Med. Sci. 73, 113–126.

Toftfjeld, M.C., Salen, P., Laporte, F., Tonelli, C., de Lorgeril, M., 2011. Dietary flavonoids increase plasma very low-chain (n-3) fatty acids in rats. J. Nutr. 141, 372–379.

Traylor, P., 2014. Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity. Annu. Rev. Nutr. 34, 207–236.

Tripp, M.L., Dahlberg, C.J., Ellyson, S., Lamb, J.J., Ou, J.J., Gao, W., Bhandari, J., Jensen, J., Bryhn, M., Pelikanova, T., 2015. Combined intervention with Metformin, Pioglitazone and n-3 fatty acids in metformin-treated type 2 diabetic patients: Interaction of a plant-based antidiabetic formulation versus well established antidiabetic molecules. Pharmacol. Res. 150, 104522.

Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., Ferrante Jr., A.W., 2009. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796–1808.

WHO, 2013. 10 Facts on Noncommunicable Diseases. WHO, 2018. Noncommunicable Diseases Fact Sheets.

WHO, 2020. Nutrition Advice for Adults during the COVID-19 Outbreak.

Wong, C.Y., Yiu, K.H., Li, S.W., Lee, S., Tam, S., Lau, C.P., Tse, H.F., 2010. Fish-oil oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus. Diabet. Med. 27, 54–60.

Yamamoto, K., Itoh, T., Abe, D., Shimizu, M., Kanda, T., Koyama, T., Nishikawa, M., Tamai, T., Oozumi, H., Yamada, S., 2005. Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents. Bioorg. Med. Chem. Lett 15, 517–522.

Young, Y.H., Nguyen, K.Y., Grant, R.W., Goldberg, E.L., Bodaghi, M., Kim, D., Agostoni, D., Planavsky, N., Lupper, C., Kanneganti, T.D., Kang, S., Horvath, T.L., Fahmy, T.M., Crawford, P.A., Bizynag, A., Almerni, E., Dixit, V.D., 2015. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 21, 263–269.

Yubero-Serrano, E.M., Gonzalez-Guardiola, L., Rangel-Zuniga, O., Delgado-List, J., Gutierrez-Mariscal, F.M., Perez-Martinez, P., Delgado-Canedo, N., Cruz-Teno, C., Tinahones, F.J., Villalba, J.M., Perez-Jimenez, F., Lopez-Miranda, J., 2012. Mediterranean diet supplemented with coenzyme Q10 modifies the expression of proinflammatory and endotelial reticulum stress-related genes in elderly men and women. J. Gerontol. A Biol. Sci. Med. Sci. 67, 3–10.

Zadeh-Ardabili, P.M., Rad, S.K., 2019. Anti-pain and anti-inflammation like effects of Neem krill oil and fish oil against carrageenan induced inflammation in mice models: current statuses and pilot study. Biotechnol. Rep. (Amst.) 22, e00341.

Zamfirescu, A., Ungurianu, A., Tsatsakis, A.M., Nitulescu, G.M., Koutetas, D., Veyckokus, A., Tsoukalas, D., Engin, A.B., Aschner, M., Margina, D., 2018. A review of the alleged health hazards of monosodium glutamate. Compr. Rev. Food Sci. Food Saf. 18, 1111–1134.

Zhang, Y., Liu, W., Zhao, T.Y., Tian, H.M., 2017. Efficacy of omega-3 polyunsaturated fatty acids supplementation in managing overweight and obesity: a meta-analysis of randomized clinical trials. J. Nutr. Health Aging 21, 187–192.

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., Cao, B., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062.

Zhou, R., Taalvèd, A., Thoren, B., Choi, I., Tschopp, J., 2010. Thioridoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11, 136–146.

Zhu, L., Shu, L., Li, K., Wang, Z., Wang, T., Li, Y., Liu, P., Dong, X., Dong, Y., Zhang, X., Wang, H., 2020. Dietary flavonoid rich oil in omega-3 suppresses severity of type 2 diabetes mellitus via anti-inflammation and modulating gut microbiota in rats. Lipids Health Dis. 19, 22254–22266.

Zhu, Y., Ling, W., Guo, H., Song, F., Ye, Q., Zou, T., Li, D., Zhang, Y., Li, G., Xiao, Y., Liu, F., Li, Z., Shi, Z., Yang, Y., 2013. Anti-inflammatory effect of purified dietary antioxidant in adults with hypercholesterolemia: a randomized controlled trial. Nutr. Metabol. Cardiovasc. Dis. 23, 843–849.